US20200325515A1 - Methods for the Enzymatic Modification of Steviol Glycosides, Modified Steviol Glycosides Obtainable Thereby, and the Use Thereof as Sweeteners - Google Patents
Methods for the Enzymatic Modification of Steviol Glycosides, Modified Steviol Glycosides Obtainable Thereby, and the Use Thereof as Sweeteners Download PDFInfo
- Publication number
- US20200325515A1 US20200325515A1 US16/899,709 US202016899709A US2020325515A1 US 20200325515 A1 US20200325515 A1 US 20200325515A1 US 202016899709 A US202016899709 A US 202016899709A US 2020325515 A1 US2020325515 A1 US 2020325515A1
- Authority
- US
- United States
- Prior art keywords
- rebaudioside
- gtf180
- glucopyranosyl
- mutant
- steviol glycoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 235000019202 steviosides Nutrition 0.000 title claims abstract description 140
- 239000004383 Steviol glycoside Substances 0.000 title claims abstract description 98
- 235000019411 steviol glycoside Nutrition 0.000 title claims abstract description 98
- 229930182488 steviol glycoside Natural products 0.000 title claims abstract description 98
- 150000008144 steviol glycosides Chemical class 0.000 title claims abstract description 98
- 235000003599 food sweetener Nutrition 0.000 title claims abstract description 35
- 239000003765 sweetening agent Substances 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title abstract description 26
- 230000009144 enzymatic modification Effects 0.000 title description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 46
- 229930006000 Sucrose Natural products 0.000 claims abstract description 46
- 239000005720 sucrose Substances 0.000 claims abstract description 46
- 230000000694 effects Effects 0.000 claims abstract description 29
- 108010048202 alternansucrase Proteins 0.000 claims abstract description 25
- 108010042194 dextransucrase Proteins 0.000 claims abstract description 24
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 14
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 14
- 239000000758 substrate Substances 0.000 claims abstract description 14
- 230000006098 transglycosylation Effects 0.000 claims abstract description 6
- 238000005918 transglycosylation reaction Methods 0.000 claims abstract description 6
- 235000013361 beverage Nutrition 0.000 claims description 30
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 28
- 239000008103 glucose Substances 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 18
- KWVKUAKMOIEELN-UHFFFAOYSA-N ent-kaur-16-en-19-oic acid Natural products CC1(C)CCCC2(C)C1CCC34CC(=C(C3)C(=O)O)CCC24 KWVKUAKMOIEELN-UHFFFAOYSA-N 0.000 claims description 12
- NIKHGUQULKYIGE-UHFFFAOYSA-N kaurenoic acid Natural products C1CC2(CC3=C)CC3CCC2C2(C)C1C(C)(C(O)=O)CCC2 NIKHGUQULKYIGE-UHFFFAOYSA-N 0.000 claims description 12
- NIKHGUQULKYIGE-SHAPNJEPSA-N ent-kaur-16-en-19-oic acid Chemical compound C([C@H]1C[C@]2(CC1=C)CC1)C[C@H]2[C@@]2(C)[C@H]1[C@](C)(C(O)=O)CCC2 NIKHGUQULKYIGE-SHAPNJEPSA-N 0.000 claims description 11
- 239000003623 enhancer Substances 0.000 claims description 8
- 239000002417 nutraceutical Substances 0.000 claims description 2
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 235000019505 tobacco product Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 124
- 239000001512 FEMA 4601 Substances 0.000 description 109
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 109
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 109
- 235000019203 rebaudioside A Nutrition 0.000 description 109
- 102000004190 Enzymes Human genes 0.000 description 54
- 108090000790 Enzymes Proteins 0.000 description 54
- 229940088598 enzyme Drugs 0.000 description 53
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 42
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 42
- 229940013618 stevioside Drugs 0.000 description 42
- 235000001727 glucose Nutrition 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 23
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 22
- -1 (sodiosulfo)propyl Chemical group 0.000 description 21
- 150000001413 amino acids Chemical class 0.000 description 21
- 238000006467 substitution reaction Methods 0.000 description 20
- 235000019658 bitter taste Nutrition 0.000 description 18
- GIPHUOWOTCAJSR-UHFFFAOYSA-N Rebaudioside A. Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC1OC(CO)C(O)C(O)C1OC(C1O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O GIPHUOWOTCAJSR-UHFFFAOYSA-N 0.000 description 16
- 235000019640 taste Nutrition 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- RPYRMTHVSUWHSV-CUZJHZIBSA-N rebaudioside D Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RPYRMTHVSUWHSV-CUZJHZIBSA-N 0.000 description 15
- 229930182478 glucoside Natural products 0.000 description 14
- 238000011534 incubation Methods 0.000 description 14
- 239000004615 ingredient Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 235000013305 food Nutrition 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- 235000009508 confectionery Nutrition 0.000 description 10
- 230000035772 mutation Effects 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 150000002772 monosaccharides Chemical class 0.000 description 9
- 229920001503 Glucan Polymers 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- 238000004809 thin layer chromatography Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 239000000386 donor Substances 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- GSGVXNMGMKBGQU-PHESRWQRSA-N rebaudioside M Chemical compound C[C@@]12CCC[C@](C)([C@H]1CC[C@@]13CC(=C)[C@@](C1)(CC[C@@H]23)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(=O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GSGVXNMGMKBGQU-PHESRWQRSA-N 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 6
- 108010025880 Cyclomaltodextrin glucanotransferase Proteins 0.000 description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 6
- QFVOYBUQQBFCRH-UHFFFAOYSA-N Steviol Natural products C1CC2(C3)CC(=C)C3(O)CCC2C2(C)C1C(C)(C(O)=O)CCC2 QFVOYBUQQBFCRH-UHFFFAOYSA-N 0.000 description 6
- 239000000370 acceptor Substances 0.000 description 6
- 239000001110 calcium chloride Substances 0.000 description 6
- 229910001628 calcium chloride Inorganic materials 0.000 description 6
- 150000002482 oligosaccharides Chemical class 0.000 description 6
- QSRAJVGDWKFOGU-WBXIDTKBSA-N rebaudioside c Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]1(CC[C@H]2[C@@]3(C)[C@@H]([C@](CCC3)(C)C(=O)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)CC3)C(=C)C[C@]23C1 QSRAJVGDWKFOGU-WBXIDTKBSA-N 0.000 description 6
- 238000001953 recrystallisation Methods 0.000 description 6
- 238000007127 saponification reaction Methods 0.000 description 6
- 239000001632 sodium acetate Substances 0.000 description 6
- 235000017281 sodium acetate Nutrition 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 206010013911 Dysgeusia Diseases 0.000 description 5
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 5
- OMHUCGDTACNQEX-OSHKXICASA-N Steviolbioside Natural products O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O OMHUCGDTACNQEX-OSHKXICASA-N 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- JLPRGBMUVNVSKP-AHUXISJXSA-M chembl2368336 Chemical compound [Na+].O([C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C([O-])=O)[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O JLPRGBMUVNVSKP-AHUXISJXSA-M 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 5
- 238000004305 normal phase HPLC Methods 0.000 description 5
- 229920001542 oligosaccharide Polymers 0.000 description 5
- 229940032084 steviol Drugs 0.000 description 5
- DRSKVOAJKLUMCL-MMUIXFKXSA-N u2n4xkx7hp Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DRSKVOAJKLUMCL-MMUIXFKXSA-N 0.000 description 5
- 239000004386 Erythritol Substances 0.000 description 4
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 4
- 229930091371 Fructose Natural products 0.000 description 4
- 239000005715 Fructose Substances 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- 101710204244 Processive diacylglycerol beta-glucosyltransferase Proteins 0.000 description 4
- 241000544066 Stevia Species 0.000 description 4
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 4
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 235000019414 erythritol Nutrition 0.000 description 4
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical group OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 4
- 229940009714 erythritol Drugs 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 239000005417 food ingredient Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 230000003301 hydrolyzing effect Effects 0.000 description 4
- 235000021580 ready-to-drink beverage Nutrition 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000012916 structural analysis Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 3
- 229920000310 Alpha glucan Polymers 0.000 description 3
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
- BJHIKXHVCXFQLS-PUFIMZNGSA-N D-psicose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C(=O)CO BJHIKXHVCXFQLS-PUFIMZNGSA-N 0.000 description 3
- LKDRXBCSQODPBY-OEXCPVAWSA-N D-tagatose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@@H]1O LKDRXBCSQODPBY-OEXCPVAWSA-N 0.000 description 3
- 239000001776 FEMA 4720 Substances 0.000 description 3
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 3
- YWPVROCHNBYFTP-UHFFFAOYSA-N Rubusoside Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC1OC(CO)C(O)C(O)C1O YWPVROCHNBYFTP-UHFFFAOYSA-N 0.000 description 3
- 230000003625 amylolytic effect Effects 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000004067 bulking agent Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000021458 diet cola Nutrition 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000001952 enzyme assay Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 235000019534 high fructose corn syrup Nutrition 0.000 description 3
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229930188195 rebaudioside Natural products 0.000 description 3
- RLLCWNUIHGPAJY-SFUUMPFESA-N rebaudioside E Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RLLCWNUIHGPAJY-SFUUMPFESA-N 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- YWPVROCHNBYFTP-OSHKXICASA-N rubusoside Chemical compound O([C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YWPVROCHNBYFTP-OSHKXICASA-N 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 238000007086 side reaction Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- GHBNZZJYBXQAHG-KUVSNLSMSA-N (2r,3r,4s,5s,6r)-2-[[(2r,3s,4s,5r,6r)-6-[[(3s,8s,9r,10r,11r,13r,14s,17r)-17-[(2r,5r)-5-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H](CC[C@@H](C)[C@@H]1[C@]2(C[C@@H](O)[C@@]3(C)[C@H]4C(C([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]6[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O6)O)O5)O)CC4)(C)C)=CC[C@H]3[C@]2(C)CC1)C)C(C)(C)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GHBNZZJYBXQAHG-KUVSNLSMSA-N 0.000 description 2
- VZQZXAJWZUSYHU-GYGGMVIMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxy-1-[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]hexan-1-one Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)C1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VZQZXAJWZUSYHU-GYGGMVIMSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- QIGJYVCQYDKYDW-UHFFFAOYSA-N 3-O-alpha-D-mannopyranosyl-D-mannopyranose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(CO)OC(O)C1O QIGJYVCQYDKYDW-UHFFFAOYSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 241000208838 Asteraceae Species 0.000 description 2
- 101100068867 Caenorhabditis elegans glc-1 gene Proteins 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- CANAPGLEBDTCAF-NTIPNFSCSA-N Dulcoside A Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@]23C(C[C@]4(C2)[C@H]([C@@]2(C)[C@@H]([C@](CCC2)(C)C(=O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)CC4)CC3)=C)O[C@H](CO)[C@@H](O)[C@@H]1O CANAPGLEBDTCAF-NTIPNFSCSA-N 0.000 description 2
- CANAPGLEBDTCAF-QHSHOEHESA-N Dulcoside A Natural products C[C@@H]1O[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2O[C@]34CC[C@H]5[C@]6(C)CCC[C@](C)([C@H]6CC[C@@]5(CC3=C)C4)C(=O)O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@H](O)[C@H](O)[C@H]1O CANAPGLEBDTCAF-QHSHOEHESA-N 0.000 description 2
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PBILBHLAPJTJOT-CQSZACIVSA-N Phyllodulcin Chemical compound C1=C(O)C(OC)=CC=C1[C@@H]1OC(=O)C2=C(O)C=CC=C2C1 PBILBHLAPJTJOT-CQSZACIVSA-N 0.000 description 2
- RLLCWNUIHGPAJY-RYBZXKSASA-N Rebaudioside E Natural products O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@@H](O)[C@@H](O)[C@H](CO)O1)[C@]1(C)[C@@H]2[C@@](C)([C@@H]3[C@@]4(CC(=C)[C@@](O[C@@H]5[C@@H](O[C@@H]6[C@@H](O)[C@H](O)[C@@H](O)[C@H](CO)O6)[C@H](O)[C@@H](O)[C@H](CO)O5)(C4)CC3)CC2)CCC1 RLLCWNUIHGPAJY-RYBZXKSASA-N 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- 239000004376 Sucralose Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- SHZGCJCMOBCMKK-HGVZOGFYSA-N alpha-L-rhamnopyranose Chemical compound C[C@@H]1O[C@@H](O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-HGVZOGFYSA-N 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014171 carbonated beverage Nutrition 0.000 description 2
- 235000012174 carbonated soft drink Nutrition 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 238000011143 downstream manufacturing Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000000348 glycosyl donor Substances 0.000 description 2
- 125000003147 glycosyl group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229930189775 mogroside Natural products 0.000 description 2
- TVJXHJAWHUMLLG-UHFFFAOYSA-N mogroside V Natural products CC(CCC(OC1OC(COC2OC(CO)C(O)C(O)C2OC3OC(CO)C(O)C(O)C3O)C(O)C(O)C1O)C(C)(C)O)C4CCC5(C)C6CC=C7C(CCC(OC8OC(COC9OC(CO)C(O)C(O)C9O)C(O)C(O)C8O)C7(C)C)C6(C)C(O)CC45C TVJXHJAWHUMLLG-UHFFFAOYSA-N 0.000 description 2
- 235000021096 natural sweeteners Nutrition 0.000 description 2
- QIGJYVCQYDKYDW-NSYYTRPSSA-N nigerose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1O QIGJYVCQYDKYDW-NSYYTRPSSA-N 0.000 description 2
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- OIPPWFOQEKKFEE-UHFFFAOYSA-N orcinol Chemical compound CC1=CC(O)=CC(O)=C1 OIPPWFOQEKKFEE-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- HYLAUKAHEAUVFE-AVBZULRRSA-N rebaudioside f Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)CO1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HYLAUKAHEAUVFE-AVBZULRRSA-N 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- QFVOYBUQQBFCRH-VQSWZGCSSA-N steviol Chemical compound C([C@@]1(O)C(=C)C[C@@]2(C1)CC1)C[C@H]2[C@@]2(C)[C@H]1[C@](C)(C(O)=O)CCC2 QFVOYBUQQBFCRH-VQSWZGCSSA-N 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- PYNUQQKEADPDEB-UHFFFAOYSA-N (+)-Hernandulcin Natural products CC(C)C=CCC(C)(O)C1CCC(=CC1=O)C PYNUQQKEADPDEB-UHFFFAOYSA-N 0.000 description 1
- CXQWRCVTCMQVQX-LSDHHAIUSA-N (+)-taxifolin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-LSDHHAIUSA-N 0.000 description 1
- RMLYXMMBIZLGAQ-UHFFFAOYSA-N (-)-monatin Natural products C1=CC=C2C(CC(O)(CC(N)C(O)=O)C(O)=O)=CNC2=C1 RMLYXMMBIZLGAQ-UHFFFAOYSA-N 0.000 description 1
- DTMJARJUCFBMFR-ZHGMGIEYSA-N (2S,3S,4S,5R,6S)-6-[[(3S,4aR,6aR,6bS,8aS,11S,12aR,14aR,14bS)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]-3,4-dihydroxy-5-[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxyoxane-2-carboxylic acid Chemical compound CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]3(C)[C@@H]2C(=O)C=C4[C@@H]5C[C@](C)(CC[C@]5(C)CC[C@@]34C)C(=O)O)O[C@H]6O[C@@H]([C@@H](O)[C@H](O)[C@H]6O[C@@H]7OC[C@H](O)[C@H](O)[C@H]7O)C(=O)O DTMJARJUCFBMFR-ZHGMGIEYSA-N 0.000 description 1
- WRPAFPPCKSYACJ-ZBYJYCAASA-N (2r,3r,4s,5s,6r)-2-[[(2r,3s,4s,5r,6r)-6-[[(3s,8r,9r,10s,11r,13r,14s,17r)-17-[(5r)-5-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2r,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-hydroxy-6-methylheptan-2-yl]-11-hydrox Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H](CCC(C)[C@@H]1[C@]2(C[C@@H](O)[C@@]3(C)[C@@H]4C(C([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]6[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O6)O)O5)O)CC4)(C)C)=CC[C@@H]3[C@]2(C)CC1)C)C(C)(C)O)[C@H]1O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]1O WRPAFPPCKSYACJ-ZBYJYCAASA-N 0.000 description 1
- GRWRKEKBKNZMOA-SJJZSDDKSA-N (2r,3r,4s,5s,6r)-2-[[(2r,3s,4s,5r,6r)-6-[[(3s,8s,9r,10r,11r,13r,14s,17r)-17-[(2r,5r)-5-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2s,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H](CC[C@@H](C)[C@@H]1[C@]2(C[C@@H](O)[C@@]3(C)[C@H]4C(C([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]6[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O6)O)O5)O)CC4)(C)C)=CC[C@H]3[C@]2(C)CC1)C)C(C)(C)O)O[C@H]1O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]1O GRWRKEKBKNZMOA-SJJZSDDKSA-N 0.000 description 1
- XJIPREFALCDWRQ-UYQGGQRHSA-N (2r,3r,4s,5s,6r)-2-[[(2r,3s,4s,5r,6s)-3,4-dihydroxy-6-[(3r,6r)-2-hydroxy-6-[(3s,8s,9r,10r,11r,13r,14s,17r)-11-hydroxy-4,4,9,13,14-pentamethyl-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3,7,8,10,11,12,15,16,17-decahydro-1h-cyclop Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H](CC[C@@H](C)[C@@H]1[C@]2(C[C@@H](O)[C@@]3(C)[C@H]4C(C([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC4)(C)C)=CC[C@H]3[C@]2(C)CC1)C)C(C)(C)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XJIPREFALCDWRQ-UYQGGQRHSA-N 0.000 description 1
- DLRVVLDZNNYCBX-BTLHAWITSA-N (2r,3r,4s,5s,6r)-6-[[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxane-2,3,4,5-tetrol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-BTLHAWITSA-N 0.000 description 1
- RMLYXMMBIZLGAQ-HZMBPMFUSA-N (2s,4s)-4-amino-2-hydroxy-2-(1h-indol-3-ylmethyl)pentanedioic acid Chemical compound C1=CC=C2C(C[C@](O)(C[C@H](N)C(O)=O)C(O)=O)=CNC2=C1 RMLYXMMBIZLGAQ-HZMBPMFUSA-N 0.000 description 1
- QZOALWMSYRBZSA-PDSBIMDKSA-N (3r,5r,8r,9r,10r,13s,14r)-3-[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-10,13-dimethyl-17-[(1s)-1-[(2r,5s,6r)-5-methyl-6-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1C[C@H]2C(=O)C[C@@H]3[C@H]4CCC([C@]4(CC[C@H]3[C@@]2(C)CC1)C)[C@H](C)[C@@H]1O[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](C)CC1)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O QZOALWMSYRBZSA-PDSBIMDKSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000012573 2D experiment Methods 0.000 description 1
- 238000012586 2D rotating frame Overhauser effect spectroscopy experiment Methods 0.000 description 1
- HJQGJABPOHIRGH-UHFFFAOYSA-N 3-[4,5-dihydroxy-6-(hydroxymethyl)-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxy-17-[5-hydroxy-6-methyl-6-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptan-2-yl]-4,4,9,13,14-pentamethyl-1,2,3,7,8,10,12,15,16,17-decahydrocyclopenta[a]phenanthren-11-one Chemical compound C1CC2(C)C3CC=C(C(C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(C)O4)O)CC4)(C)C)C4C3(C)C(=O)CC2(C)C1C(C)CCC(O)C(C)(C)OC1OC(CO)C(O)C(O)C1O HJQGJABPOHIRGH-UHFFFAOYSA-N 0.000 description 1
- PBILBHLAPJTJOT-UHFFFAOYSA-N 3S-phyllodulcin Natural products C1=C(O)C(OC)=CC=C1C1OC(=O)C2=C(O)C=CC=C2C1 PBILBHLAPJTJOT-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 229930191364 Abrusoside Natural products 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- DTMJARJUCFBMFR-UHFFFAOYSA-N Araboglycyrrhizin Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OCC(O)C(O)C1O DTMJARJUCFBMFR-UHFFFAOYSA-N 0.000 description 1
- ZROGCCBNZBKLEL-FHXNIQKESA-N Astilbin Natural products O([C@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O)[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 ZROGCCBNZBKLEL-FHXNIQKESA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- VBEIDHOJIRRYJX-UHFFFAOYSA-N Bryoside Natural products CC(C(O)CCC(C)(C)OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CC=C5C(CCC(OC6OC(CO)C(O)C(O)C6OC7OC(C)C(O)C(O)C7O)C5(C)C)C4(C)C(=O)CC23C VBEIDHOJIRRYJX-UHFFFAOYSA-N 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- VUNMMSWSCNIWFF-CIGQWFENSA-N C=C1C[C@@]23CCC4[C@@](C)(CCC[C@@]4(C)C(=C)O[C@@H]4OC(CO[C@H]5OC(CO)[C@@H](O)C(O)[C@@H]5O)[C@@H](O)C(O)C4O)C2CC[C@]1(O[C@@H]1OC(CO)[C@@H](O)C(O[C@@H]2OC(CO)[C@@H](O)[C@H](O)C2O)[C@@H]1O[C@@H]1OC(CO)[C@@H](O)[C@H](O)C1O)C3 Chemical compound C=C1C[C@@]23CCC4[C@@](C)(CCC[C@@]4(C)C(=C)O[C@@H]4OC(CO[C@H]5OC(CO)[C@@H](O)C(O)[C@@H]5O)[C@@H](O)C(O)C4O)C2CC[C@]1(O[C@@H]1OC(CO)[C@@H](O)C(O[C@@H]2OC(CO)[C@@H](O)[C@H](O)C2O)[C@@H]1O[C@@H]1OC(CO)[C@@H](O)[C@H](O)C1O)C3 VUNMMSWSCNIWFF-CIGQWFENSA-N 0.000 description 1
- 101100068866 Caenorhabditis elegans glc-2 gene Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229930186291 Dulcoside Natural products 0.000 description 1
- 229920002444 Exopolysaccharide Polymers 0.000 description 1
- 239000001183 FEMA 4495 Substances 0.000 description 1
- 239000001689 FEMA 4674 Substances 0.000 description 1
- 102000005731 Glucose-6-phosphate isomerase Human genes 0.000 description 1
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- GLLUYNRFPAMGQR-UHFFFAOYSA-N Glycyphyllin Natural products OC1C(O)C(O)C(C)OC1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 GLLUYNRFPAMGQR-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- HYQNKKAJVPMBDR-UHFFFAOYSA-N Hernandulcin Natural products CC(C)=CCCC(C)(O)C1CCC(C)=CC1=O HYQNKKAJVPMBDR-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- ZROGCCBNZBKLEL-AEGLVIMLSA-N Isoastibin Natural products O([C@@H]1[C@H](c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O)[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 ZROGCCBNZBKLEL-AEGLVIMLSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- 241001468192 Leuconostoc citreum Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108050004114 Monellin Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- CWBZAESOUBENAP-QVNVHUMTSA-N Naringin dihydrochalcone Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C(O)C(C(=O)CCC=3C=CC(O)=CC=3)=C(O)C=2)O[C@H](CO)[C@@H](O)[C@@H]1O CWBZAESOUBENAP-QVNVHUMTSA-N 0.000 description 1
- 239000004384 Neotame Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- QZOALWMSYRBZSA-UHFFFAOYSA-N Osladin Natural products C1CC(C)C(OC2C(C(O)C(O)C(C)O2)O)OC1C(C)C(C1(CCC2C3(C)CC4)C)CCC1C2CC(=O)C3CC4OC1OC(CO)C(O)C(O)C1OC1OC(C)C(O)C(O)C1O QZOALWMSYRBZSA-UHFFFAOYSA-N 0.000 description 1
- 101000865553 Pentadiplandra brazzeana Defensin-like protein Proteins 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- 241001092459 Rubus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 1
- 229930182647 Trilobatin Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- NKAYJMFKKMUJQU-ZFIFBBNOSA-N [(2s,3r,4r,5r)-3,4-dihydroxy-5-[[(10r,12s,14r)-17-[(2s)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-4,4,7,10,14-pentamethyl-12-[(2r,3r,4s,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-1,2,3,5,6,7,8,9,11,12,13,15,16,17-tetradecahydrocyclopenta[a]phenanth Chemical compound O([C@H]1CC2[C@@]3(C)CCC(C(C)(C)C3CC(C2[C@@]2(C)CCC(C21)[C@@]1(C)OC(CC1)C(C)(C)O)C)O[C@H]1[C@@H]([C@@H](O)[C@H](COC(C)=O)O1)O)[C@@H]1O[C@@H](C)[C@H](O)[C@H](O)[C@H]1O NKAYJMFKKMUJQU-ZFIFBBNOSA-N 0.000 description 1
- XSDXQNVJNSCZNC-UHFFFAOYSA-N [5,7-dihydroxy-2-(4-methoxyphenyl)-4-oxo-2,3-dihydrochromen-3-yl] acetate Chemical compound C1=CC(OC)=CC=C1C1C(OC(C)=O)C(=O)C2=C(O)C=C(O)C=C2O1 XSDXQNVJNSCZNC-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 229930193947 albiziasaponin Natural products 0.000 description 1
- 125000003691 alpha-D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- WQZGKKKJIJFFOK-PQMKYFCFSA-N alpha-D-mannose Chemical compound OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-PQMKYFCFSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012431 aqueous reaction media Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- JOKKBOSZTVHKSH-UHFFFAOYSA-N baiyunoside Natural products CC12CCC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)CO3)O)C(C)(C)C1CCC(C)=C2CCC=1C=COC=1 JOKKBOSZTVHKSH-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-KKQCNMDGSA-N beta-D-xylose Chemical group O[C@@H]1CO[C@@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-KKQCNMDGSA-N 0.000 description 1
- 239000011942 biocatalyst Substances 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 235000019611 bitter taste sensations Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- NYEPTLBRUYNTIS-UHFFFAOYSA-N bryonoside Natural products CC(CCC(O)C(C)(C)OC1OC(CO)C(O)C(O)C1OC2OC(CO)C(O)C(O)C2O)C3CCC4(C)C5CC=C6C(CCC(OC7OC(CO)C(O)C(O)C7OC8OC(C)C(O)C(O)C8O)C6(C)C)C5(C)C(=O)CC34C NYEPTLBRUYNTIS-UHFFFAOYSA-N 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 108010010165 curculin Proteins 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000007673 developmental toxicity Effects 0.000 description 1
- 231100000415 developmental toxicity Toxicity 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- XCGZWJIXHMSSQC-UHFFFAOYSA-N dihydroquercetin Natural products OC1=CC2OC(=C(O)C(=O)C2C(O)=C1)c1ccc(O)c(O)c1 XCGZWJIXHMSSQC-UHFFFAOYSA-N 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000007323 disproportionation reaction Methods 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000021554 flavoured beverage Nutrition 0.000 description 1
- 239000012628 flowing agent Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002178 gastroprotective effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- GLLUYNRFPAMGQR-PPNXFBDMSA-N glycyphyllin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 GLLUYNRFPAMGQR-PPNXFBDMSA-N 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- QRVGJSHXWIIHPI-UHFFFAOYSA-N huangqioside E Natural products CC1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C(OC5OC(CO)C(O)C(O)C5O)C1O QRVGJSHXWIIHPI-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 229930191869 mogroside IV Natural products 0.000 description 1
- OKGRRPCHOJYNKX-UHFFFAOYSA-N mogroside IV A Natural products C1CC2(C)C3CC=C(C(C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)C(CO)O5)O)O4)O)CC4)(C)C)C4C3(C)C(O)CC2(C)C1C(C)CCC(C(C)(C)O)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O OKGRRPCHOJYNKX-UHFFFAOYSA-N 0.000 description 1
- WRPAFPPCKSYACJ-UHFFFAOYSA-N mogroside IV E Natural products C1CC2(C)C3CC=C(C(C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)C(CO)O5)O)O4)O)CC4)(C)C)C4C3(C)C(O)CC2(C)C1C(C)CCC(C(C)(C)O)OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O WRPAFPPCKSYACJ-UHFFFAOYSA-N 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- ZROGCCBNZBKLEL-MFSALPCASA-N neoastilbin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C(=O)C2=C(O)C=C(O)C=C2O[C@H]1C1=CC=C(O)C(O)=C1 ZROGCCBNZBKLEL-MFSALPCASA-N 0.000 description 1
- ZROGCCBNZBKLEL-RMPKKLJSSA-N neoastilbin Natural products C[C@@H]1O[C@H](O[C@H]2[C@@H](Oc3cc(O)cc(O)c3C2=O)c2ccc(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O ZROGCCBNZBKLEL-RMPKKLJSSA-N 0.000 description 1
- 235000019412 neotame Nutrition 0.000 description 1
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 description 1
- 108010070257 neotame Proteins 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000019533 nutritive sweetener Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000000238 one-dimensional nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 229930183085 periandrin Natural products 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- FAASKPMBDMDYGK-UHFFFAOYSA-N phlomisoside I Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC1C(C)(C)C(CCC(C)=C2CCC3=COC=C3)C2(C)CC1 FAASKPMBDMDYGK-UHFFFAOYSA-N 0.000 description 1
- 229930183383 polypodoside Natural products 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 238000000079 presaturation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229930185946 pterocaryoside Natural products 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- QRGRAFPOLJOGRV-UHFFFAOYSA-N rebaudioside F Natural products CC12CCCC(C)(C1CCC34CC(=C)C(CCC23)(C4)OC5OC(CO)C(O)C(OC6OCC(O)C(O)C6O)C5OC7OC(CO)C(O)C(O)C7O)C(=O)OC8OC(CO)C(O)C(O)C8O QRGRAFPOLJOGRV-UHFFFAOYSA-N 0.000 description 1
- 230000007696 reproductive toxicity Effects 0.000 description 1
- 231100000372 reproductive toxicity Toxicity 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000030812 sensory perception of bitter taste Effects 0.000 description 1
- 230000030738 sensory perception of sweet taste Effects 0.000 description 1
- XJIPREFALCDWRQ-UHFFFAOYSA-N siamenoside I Natural products C1CC2(C)C3CC=C(C(C(OC4C(C(O)C(O)C(CO)O4)O)CC4)(C)C)C4C3(C)C(O)CC2(C)C1C(C)CCC(C(C)(C)O)OC(C(C(O)C1O)OC2C(C(O)C(O)C(CO)O2)O)OC1COC1OC(CO)C(O)C(O)C1O XJIPREFALCDWRQ-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000001551 total correlation spectroscopy Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- GSTCPEBQYSOEHV-QNDFHXLGSA-N trilobatin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C=C1O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 GSTCPEBQYSOEHV-QNDFHXLGSA-N 0.000 description 1
- 238000004104 two-dimensional total correlation spectroscopy Methods 0.000 description 1
- 235000015192 vegetable juice Nutrition 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000004329 water eliminated fourier transform Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/44—Preparation of O-glycosides, e.g. glucosides
- C12P19/56—Preparation of O-glycosides, e.g. glucosides having an oxygen atom of the saccharide radical directly bound to a condensed ring system having three or more carbocyclic rings, e.g. daunomycin, adriamycin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/60—Sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/30—Artificial sweetening agents
- A23L27/33—Artificial sweetening agents containing sugars or derivatives
- A23L27/36—Terpene glycosides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/86—Addition of bitterness inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A23Y2220/71—
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Obesity (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Seasonings (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Saccharide Compounds (AREA)
Abstract
The present invention relates generally to the production of steviol glycosides. Provided is a method for enzymatically providing a modified steviol glycoside, comprising incubating a steviol glycoside substrate in the presence of sucrose and the glucansucrase GTF180 of Lactobacillus reuteri strain 180, or a mutant thereof having the desired transglycosylation activity. Also provided are modified steviol glycosides obtainable by a method of the invention, and the use thereof as low-glycemic sweetener.
Description
- This application is a divisional application which claims priority to U.S. patent application Ser. No. 15/556,846, filed on Sep. 8, 2017, which is a National Stage Application under 35 U.S.C. 371 of co-pending PCT application number PCT/NL2016/050172 designating the United States and filed Mar. 10, 2016; which claims the benefit of EP application number 15158421.6 and filed Mar. 10, 2015 each of which are hereby incorporated by reference in their entireties.
- The present invention relates generally to the production of steviol glycosides. Particularly, the invention relates to methods for the enzymatic modification of steviol glycosides to novel steviol glycosides, and use thereof as sweeteners.
- Sweeteners are well known as ingredients used most commonly in the food, beverage, or confectionary industries. The sweetener can either be incorporated into a final food product during production or for stand-alone use, e.g. when appropriately diluted or as a tabletop sweetener. Sweeteners include natural sweeteners such as sucrose, high fructose corn syrup, molasses, maple syrup, and honey and artificial sweeteners such as aspartame, saccharine and sucralose.
- The leaves of the herb plant Stevia rebaudiana Bertoni, a rhizomatous perennial shrub of the Asteraceae [Compositae] family, contain a high variety of natural sweet compounds, being steviol glycosides (Brandle et al. 1998). Stevioside (5-10% w/w of dried leaves) and Rebaudioside A (2-4% w/w of dried leaves) are the most abundant and they taste about 200-300 times sweeter than sucrose (0.4% water solution). Therefore, they can be considered as “bio” alternatives for sucrose and for artificial (synthetic) sweeteners (Geuns 2003; Goyal et al. 2010; Puri et al. 2011).
- In addition to sweetness, some steviol glycosides, in higher doses and regular consumption, possess diverse pharmacological properties, like antioxidant, antibacterial, antifungal, antiviral, antitumor, gastro protective (antidiarrheal), and they seem to have a positive effect on renal function, blood pressure and blood glucose levels (Chatsudthipong and Muanprasat 2009; Madan et al. 2010; Brahmachari et al. 2011; Lemus-Mondaca et al. 2012; Shivanna et al. 2013). They can be of benefit to people suffering from obesity, diabetes mellitus, hypertension, phenylketonuria, heart disease and dental caries (Yadav and Guleria 2012). Steviol glycosides are non-caloric, not carcinogenic, not genotoxic and not associated with any reproductive/developmental toxicity in humans (European Food Safety Authority, 2010).
- Structurally, steviol glycosides have an ent-13-hydroxykaur-16-en-19-oic acid as aglycone but differ in carbohydrate composition (see
FIG. 1 ). - The ratio of the number of glucose units at the 13-tert-hydroxyl group to that at 19-carboxyl group seems to have a relationship with the sweetness as well as with the quality of taste of the steviol glycosides (Darise et al. 1984). For instance, Rebaudioside A is less bitter than Stevioside. Enzymatic glucosylation studies of Stevioside show that the glycosidic linkage specificity affects the organoleptic properties of steviol glycosides as well. Fukunaga et al. (1989) found that both mono- and di-(α1→4)-glucosylation of Stevioside at the C-13-position gave products with remarkable improvement in both the intensity and quality of the sweetness. However, both mono- and di-(α1→4)-glycosylation at the C-19 position resulted in an increased bitter aftertaste and a lower sweetness intensity (Fukunaga et al. 1989). On the other hand, attachment of an α-linked glucose to the C-6 hydroxyl group of the glucose unit at the C-19-position led to a remarkable improvement in the quality of taste (Lobov et al. 1991). Apparently, the anomericity of the glycosidic bond does not influence sweet and bitter taste perception to a great extent, since several recent studies show that Rebaudioside D and Rebaudioside M, both Rebaudioside A derivatives with respectively one and two 6-linked glucose units extra at the 19-O-glucosyl moiety, both have a more desirable taste profile than Rebaudioside A and many other steviol glycosides (Hellfritsch et al. 2012; US 2013/00771521A1; WO2014/122227; Prakash et al. 2014). Compared to Rebaudioside A, Rebaudioside D has increased sweetness and decreased bitterness in water and in carbonated beverage base. Rebaudioside M showed reduced bitterness compared to Rebaudioside A but similar sweetness intensity in water solution. In acidified water a reduced bitterness and higher sweetness were perceived compared to Rebaudioside A (Prakash et al. 2014). Moreover, attachment of an (α1→2)- or an (β1→2)-(is Rebaudioside E)-linked glucose to the C-2 hydroxyl group of the glucose unit at the C-19-position of Stevioside improved the organoleptic products of Stevioside, yielding compounds with similar sweetness, but with reduced bitterness (Ye et al. 2013).
- The main drawback for successful commercialization of Stevia sweeteners is their slight bitterness and astringency (Stevioside in particular). These undesirable properties can be reduced or eliminated by modifying the glycosyl moieties of the steviol glycosides.
- Chemical modifications of steviol glycosides have been performed with the aim of improving the quality of taste of these compounds. For instance, Stevioside and Rebaudioside A could be improved by replacement of the 19-O-glucosyl residues by a (sodiosulfo)propyl [(CH2)3SO3Na] moiety (DuBois et al. 1981; DuBois and Stephenson 1985). Furthermore, several analogs of stevioside have been synthesized by replacing the C-19-O-β-D-glucosyl moiety for another monosaccharide (e.g. β-D-Xyl, α-L-Ara, α-D-Man, or α-L-Rha) or extension of the C-19 β-D-glucosyl moiety with a monosaccharide (α-L-Rha or α-L-Qui). However, it is generally held that the application of chemical methods to modify steviol glycosides is impractical, due to the need of multistep sequences in the selective protection-deprotection synthesis strategies. Furthermore, the use of organic solvents and metallic salts will cause problems for acceptation of the obtained derivatives in the food industry. To overcome these problems, biocatalyst alternatives are more preferred, also with the objectives of “green” chemistry.
- A promising procedure is to subject steviol glycosides to the reaction of enzymatic transglycosylation, thereby introducing new monosaccharide residues into the molecule. Depending on the number, position and anomericity of the monosaccharide residues, the taste quality and potency of the compounds will vary.
- To improve the taste, enzymatic modifications of the carbohydrate moieties of steviol glycosides have been performed by using different enzyme systems, amongst which UDP-glucosyltransferases (UGTases)(WO2013/176738A9; WO 2014/122227) and cyclodextrin glucanotransferases (CGTases) (Darise et al 1984; Li et al 2013; US2014/0227421A1). UGTases are efficient enzymes with high regio-specificity, catalyzing the transfer of α- or β-linked glucoses at a specific location. However, UGTases require expensive nucleotide activated sugars as glycosyl donor, which makes them less attractive for industrial applications. CGTases catalyze coupling and disproportionation reactions, transferring glucose residues from starch or cyclodextrins to acceptor molecules. The intermolecular transglucosylation reaction is expected to occur exclusively at the C-4-hydroxyl group of the non-reducing-end glucose residues of the steviol glycosides due to the acceptor specificity of the CGTase enzyme. Although often high yields are obtained, CGTase has poor C-13/C-19 regio-specificity producing steviol glycosides that are mostly mixtures of compounds with α-D-glucosyl extensions at C-13 and C-19. Furthermore, the (α1→4)-linkages introduced by CGTase enzymes are rapidly hydrolyzed in the human mouth by the amylolytic enzymes present in saliva, thereby increasing the caloric content of steviol glycosides. Introduction of a-amylase resistant glycosidic linkages, such as the (α1→6) and (α1→3) linkages, is therefore more desirable, since it will answer the consumers demand for low and zero calorie food products.
- Accordingly, the present inventors aimed for novel means and methods to provide enzymatically modified steviol glycosides. In particular, they set out to develop an enzymatic method yielding compounds showing a reduced bitterness and/or higher sweetness compared to the unmodified steviol glycoside. Preferably, the method is economically attractive at an industrial scale, and preferably does not require expensive nucleotide activated sugars as glycosyl donor.
- To that end, they screened the glucosylation potential of glucansucrase and fructansucrase enzymes of different lactobacilli, of which most members have the generally-recognized-as-safe (GRAS) status, such as Lactobacillus reuteri. Glucansucrases are extracellular enzymes, which are only reported to occur in lactic acid bacteria. They synthesise a-glucan polymers from the cheap donor substrate sucrose. Depending on the glucansucrase enzyme, different (mixtures of) glycosidic linkages are introduced in their glucan products, namely (α1→2)-, (α1-3)-, (α1→4)- and (α1→6)-linkages (Leemhuis et al. 2013). The low cost of the glucosyl donor substrate sucrose used by glucansucrase enzymes is a major advantage for their industrial applications. Most importantly, the (α1→2)-, (α1→3)- and (α1→6)-linkages introduced by glucansucrase enzymes are not hydrolyzed in the mouth by the amylolytic enzymes present in saliva. More than 100 enzymes consisting of wild-type and mutant glucansucrase and fructansucrase enzymes with different product specificity from different Lactobacillus reuteri strains, were screened for their ability to glucosylate the steviol glycoside Rebaudioside A. Rebaudioside A glucosides were isolated by semi-preparative NP-HPLC and their structures were elucidated by MALDI-TOF mass spectrometry and 1D/2D 1H/13C NMR spectroscopy. Sensory evaluations were performed to determine the taste attributes of the novel Rebaudioside A glucosides.
- It was surprisingly found that only the glucansucrase GTF180 from Lactobacillus reuteri 180 (GenBank accession number AY697430) was able to glucosylate Rebaudioside A. NMR structural analysis of the Rebaudioside A glucosylation products showed that GTF180 specifically and only glucosylates Rebaudioside A at the C-19 β-linked glucose residue. Interestingly, several GTF180 point mutants displayed much higher transglucosylating activity towards Rebaudioside A. One mutant, Q1140E, even showed ˜96% Rebaudioside A conversion. Similar results were observed with respect to modification of Stevioside.
- Accordingly, in one embodiment the invention provides a method for enzymatically providing a modified steviol glycoside, comprising incubating a steviol glycoside substrate in the presence of a glucose donor and the glucansucrase GTF180 of Lactobacillus reuteri strain 180, or a mutant thereof having the desired transglycosylation activity.
- To our knowledge there is only one report on glucosylation of stevioside using glucansucrases. Musa et al. reported the enzymatic modification by alternansucrase from Leuconostoc citreum SK24.002 in the biotransformation of stevioside to fully or partially remove the bitter taste of the stevioside. With optimized reaction conditions a maximum transglucosylation yield of 43.7% was achieved with stevioside. Stevioside glycosides with 1 to 3 α-glucose units attached were obtained. In a follow-up study the structure of the product was characterized to be 13-{[α-D-glucopyranosyl-(1→3)-α-D-glucopyranosyl-(1→6)-α-D-glucopyranosyl-(1→3)-8-D-glucopyranosyl-(1→2)-β-D-glucopyranosyl]oxy}ent-kaur-16-en-19-oic acid β-D-glucopyranosyl ester (Musa et al. 2014). Thus, the method of Musa et al. uses a distinct enzyme, shows a lower yield and results in a distinct type of modification, namely α-glucosylation at the C-13 site instead of at the C-19 site.
- In one embodiment of the present invention, the steviol glycoside is modified with at least one α-glucose residue at the C-19 β-linked glucose residue. For example, the steviol glycoside is provided with one or more glucoses via an (α1→6), an (a 1→3) glycosidic bond, or a combination thereof. In a specific aspect, the modification involves the addition of one glucose via an (α1→6) glycosidic bond (β-isomaltose) or an (α1→3) glycosidic bond (P-nigerose) (
FIG. 5A ). In another specific aspect, the modification involves the addition of a glucosyl-glucose unit via an (α1→6) glycosidic bond at the β-linked glucose. Within the unit, the glucose residues can be connected via an (α1→6) glycosidic bond (isomaltose) or an (α1→3) glycosidic bond (nigerose) (FIGS. 5B and 5C ). - A steviol glycoside can be modified at multiple positions. For example, modifications can occur at the C-13 and/or the C-19 position(s) of the steviol aglycone. In view of the attractive taste characteristics of Rebaudioside D and Rebaudioside M, the steviol glycoside is preferably at least modified at the C-19 site of the steviol glycoside.
- More preferably, the modified steviol glycoside is only modified at the C-19 site of the steviol glycoside. For example, in one embodiment the invention provides a method for the enzymatic production of a modified steviol glycoside, which is only modified with a single glucose residue at the C-19 position of the steviol aglycone. In one embodiment, the modification comprises the addition of a single (α1→6) glucose at the C-19 β-linked glucose residue.
- The steviol glycoside substrate can be of any type. For example, it is selected from the group consisting of Stevioside, Rubusoside, Rebaudiosides including Rebaudioside A, Rebaudioside C, Rebaudioside D, and Rebaudioside E, and Dulcoside compounds. In one embodiment, the steviol glycoside substrate has at least one monosaccharide moiety at the C-19 position of the steviol glycoside.
- In one specific embodiment, the steviol glycoside substrate is a Rebaudioside. The present inventors hypothesized that α-glucosylation of Rebaudioside A at the C-19 site could thus yield Rebaudioside D and Rebaudioside M anomeric isomers with a similar or even better taste profile than Rebaudioside D and Rebaudioside M. Accordingly, in a preferred embodiment, the invention provides a method for enzymatic modification of Rebaudioside A [13-({β-D-glucopyranosyl-(1→2)-[β-D-glucopyranosyl-(1→3)-]β-D-glucopyranosyl}oxy)ent-kaur-16-en-19-oic acid α-D-glucopyranosyl ester].
- In another specific embodiment, the steviol glycoside substrate is Stevioside, the most abundant and one of the bitterest tasting steviol glycosides present in Stevia extracts.
- Typically, on a dry weight basis, the four major steviol glycosides found in the leaves of Stevia are Dulcoside A (0.3%), Rebaudioside C (0.6-1.0%), Rebaudioside A (2-4%) and Stevioside (5-10%). Other glycosides identified in reasonable amounts in Stevia extract include Rebaudioside B, D, E, and F, Steviolbioside and Rubusoside. Among these, only Stevioside and Rebaudioside A are currently available on a commercial scale.
- Steviol glycosides can be extracted from leaves using methods known in the art, typically involving either water or organic solvent extraction. Supercritical fluid extraction and steam distillation methods have also been described. Methods for the recovery of diterpene sweet glycosides from Stevia rebaudiana using supercritical CO2, membrane technology, and water or organic solvents, such as methanol and ethanol, may also be used.
- US2014/343262 discloses a method for purifying steviol glycosides, comprising the steps of: a. passing a solution of steviol glycosides through a multi-column system including a plurality of columns packed with adsorbent resin, to provide at least one column having adsorbed steviol glycosides; and b. eluting fractions with low Rebaudioside X (was later named as Rebaudioside M (US 2014/0227421; Prakash et al 2014) content from at least one column having adsorbed steviol glycosides to provide an eluted solution comprising steviol glycosides.
- Rebaudioside A is generally available at ≤80% purity. The primary impurities comprise Stevioside, Steviolbioside, Rebaudioside B, Rebaudioside C, Rebaudioside D, Dulcoside A, Rebaudioside F, and other steviol glycosides. Many studies focused on the recovery of a high purity of Rebaudioside A in high recovery. U.S. Pat. No. 5,962,678 discloses the re-crystallization of Rebaudioside A using an anhydrous methanol solution to obtain an 80% pure Rebaudioside A. By repeating the re-crystallization with anhydrous methanol numerous times, the purity of rebaudioside A may be increased to over 95%. US 2006/0083838 discloses purification of Rebaudioside A through re-crystallization with a solvent comprising ethanol and between 4 and 15% water. Japanese Patent Application No. 55-23756 discloses a method for purifying rebaudioside A and stevioside by crystallization from aqueous ethanol (>70%) to obtain an 80% pure Rebaudioside A. US 2007/0082103 discloses a method for purifying Rebaudioside A by recrystallization from aqueous ethanol, asserting a two-step recrystallization from crude Rebaudioside (60%) results in the formation of at least 98% pure Rebaudioside A at 97% yield. U.S. Pat. No. 8,791,253 provides a substantially pure Rebaudioside A composition using only a single recrystallization step.
- The concentration of steviol glycoside substrate in a method of the invention can vary e.g. depending on type of substrate, desired modification, etc. Typically, the reaction mixture comprises at least 20 mM steviol glycoside to be modified, preferably at least 30 mM, more preferably at least 50 mM, like 60, 70, 80 90 to 100 mM. The maximal concentration is among others dependent on the substrate solubility in an aqueous reaction medium. For example, good results were obtained using 50 to 100 mM Rebaudioside A or Stevioside as substrate.
- A method of the invention uses sucrose as glucose donor. Sucrose is cheap and widely available. Good results were obtained when sucrose is used at a concentration of at least 50 mM, preferably at least 100 mM, more preferably at least 500 mM. For example, the reaction mixture comprises at least 500 mM, 600 mM, 700 mM, 800 mM, 900 mM or 1 M sucrose. Even higher concentrations, like up to 2 M or 3 M, may be used. The glucose donor can in its total amount be added at the onset of the reaction. In some embodiment, it is advantageous to add sucrose in a batch wise manner. For example, sucrose is added in a batch wise manner, e.g. at the onset, after 1.5 and 3 hours, to a final amount of at least 1 M, more preferably at least 2 M.
- The reaction is typically performed at a temperature of about 20 to 70° C., in the pH range of 3-7. Preferably, a temperature of about 37° C. is used.
- The reaction is allowed to proceed until a desirable amount of modified steviol glycoside is produced. Typically, incubations are performed during a period ranging from about 1 hour to overnight.
- The skilled person will be able to determine the amount of GTF180 glucansucrase enzyme to be used to obtain a desirable degree of enzymatic modification under the given reaction conditions. For example, 1 to 50 U/mL can be used. Preferably, at least 3 U/mL is used. For economical reasons, it may be advantageous to use up to 35 U/mL. In one embodiment, 5 to 30 U/mL is used. One unit (U) of enzyme is defined as the amount of enzyme required for producing 1 μmol monosaccharide per minute in a reaction mixture containing 25 mM sodium acetate (pH 4.7); 1 mM CaCl2); and 1 M sucrose at 37° C.
- In one embodiment, wild-type GTF180 glucansucrase from Lactobacillus reuteri strain 180 is used (GenBank accession number AY697430). In another embodiment, a mutant GTF180 glucansucrase is used. As used herein, a mutant GTF180 glucansucrase refers to an enzyme comprising one or more amino acid substitutions, amino acid deletions and/or amino acid insertions as compared to the wild type amino acid sequence.
- In a preferred embodiment, a GTF180 mutant for enzymatic modification of a steviol glycoside according to the present invention comprises a substitution mutation at positions S1137, Q1140, L981 and/or W1065 (numbering based on the GenBank sequence AY697430). Preferably, the mutation is a non-conservative substitution i.e. a mutation that results in an amino acid change that has different properties than the native amino acid. For example, said mutant has one or more of the following amino acid substitutions: S1137Y, Q1140E, L981A, W1065L/E/Q/F.
- In another embodiment, a mutant GTF180 is a deletion mutant or truncated variant, wherein a stretch of at least 10 amino acids is removed from the N- and/or C-terminus. In one aspect, the truncation mutant is GTF180-ΔN comprising residues 742-1772, in which the N-terminal variable domain has been deleted. For example, good results were obtained with GTF180-ΔN which is the 117 kDa N-terminally truncated (741 residues) fragment of the GTF180 full-length wild type protein. GTF180-ΔN is fully active and produces an α-glucan polymer with similar size and linkage distribution as the full length enzyme (Kralj et al. 2004a). NMR structural analysis of the Rebaudioside A glucosylation products showed that GTF180-ΔN specifically and only glucosylates Rebaudioside A at the C-19 8-linked glucose residue. Interestingly, several GTF180-ΔN substitution mutants displayed much higher transglucosylating activity towards Rebaudioside A than GTF180-ΔN. One mutant, Q1140E, even showed 96% Rebaudioside A conversion compared to ˜55% Rebaudioside A conversion by GTF180-ΔN (
FIG. 3 andFIG. 4 ). Accordingly, in a preferred embodiment a method of the invention uses GTF180-ΔN with one or more amino acid substitutions, for example at position Q1140, S1137, L981, and/or W1065. Specific exemplary mutant enzymes include GTF180-ΔNQ1140E, GTF180-ΔNQ1140F, GTF180-ΔNQ1140N, GTF180-ΔNQ1140Y, GTF180-ΔNQ1140R, GTF180-ΔNS1137Y, GTF180-ΔN L981A, GTF180-ΔN W1065L, GTF180-ΔN W1065E, GTF180-ΔN W1065 Q and GTF180-ΔN W1065F. - In another aspect, the truncation mutant is GTF180-ΔNΔV, in which both the N-terminal variable domain and N-terminal domain V fragment (corresponding to the first 793 N-terminal amino acids), and the domain V C-terminal fragment (corresponding to the last 136 C-terminal amino acids) have been deleted (Meng et al. 2015a) to result in a GTF180 mutant consisting of amino acids 794-1636. This GTF180-ΔNΔV truncation mutant, which may be considered as the “catalytic core”, has a ˜50% reduction in size compared to the full length GTF180 wild type, is fully active, creates a similar glycosidic linkage distribution as GTF180 wild type, but is heavily impaired in high-molecular-mass polysaccharide synthesis.
- A truncation mutant of the invention may additionally contain substitution mutation(s), e.g. to improve its catalytic properties. In one embodiment, the mutant is GTF180-ΔNΔV, furthermore comprising a substitution mutation at position(s) S1137, Q1140, L981 and/or W1065. For example, said mutant has one or more of the following amino acid substitutions: S1137Y, Q1140E, L981A, W1065L/E/Q/F. Specific exemplary mutant enzymes include GTF180-ΔNΔVQ1140E, GTF180-ΔNΔVQ1140F, GTF180-ΔNΔVQ1140N, GTF180-ΔNΔVQ1140R GTF180-ΔNΔVQ1140Y, GTF180-ΔNΔVS1137Y, GTF180-ΔNΔV L981A, GTF180-ΔNΔV W1065L, GTF180-ΔNΔV W1065E, GTF180-ΔNΔV W1065 Q and GTF180-ΔNΔV W1065F.
- Mutant GTF180 glucansucrases have for example been described by Van Leeuwen et al. reporting the mutagenesis of specific amino acid residues of the GTF180-ΔN enzyme, which yielded 12 mutant enzymes that produce modified exopolysaccharides (mEPSs) from sucrose (van Leeuwen et al. 2009). It was found by the present inventors that two of the single mutants, Q1140E and S1137Y of GTF180-ΔN, displayed much higher transglucosylating activity towards Rebaudioside A than GTF180-ΔN, showing respectively ˜96% and ˜73% Rebaudioside A conversion compared to ˜55% Rebaudioside A conversion by GTF180-ΔN (
FIG. 3 andFIG. 4 ). Mutant Q1140E mainly produced mono-α-glucosylated Rebaudioside A, while GTF180-ΔN and mutant S1137Y produced multiple-α-glucosylated forms with DP up to at least 8. NMR structural analysis of the α-glucosylated products showed that GTF180-ΔN and mutants Q1140E and S1137Y specifically and only glucosylate Rebaudioside A at the C-19 site. The three enzymes glucosylated Rebaudioside A exclusively with an (α1→6)-linked glucose at the C-19 β-linked glucose, yielding RebAG1. The di-glucosylated Rebaudioside A products of GTF180-ΔN and mutant S1137Y were both elongations of RebAG1 with an (α1→3)-linked glucose (˜75%) or another (α1-6)-linked glucose (˜25%) coupled at the terminal α-glucose residue. Accordingly, specifically preferred mutants include Q1140E and S1137Y of GTF180-ΔN. - GTF180-ΔN mutants L981A and W1065L/E/Q/F (Meng et al. 2015b) are able to α-glucosylate Rebaudioside A, but show almost no polymerization (i.e. oligosaccharide and glucan formation) activity. This is a clear advantage during downstream processing, the purification of elongated Rebaudioside A products from mono- and disaccharides, oligosaccharides and glucans. By eliminating α-glucan synthesis, the most important side reaction, higher glycosylation yields were obtained for Rebaudioside A. At 200 mM sucrose and 1.5 hour incubation time, these mutants have similar or even higher transglucosylating activity than GTF180-ΔN and mutants Q1140E and S1137Y on Rebaudioside A. As observed with Rebaudioside A as acceptor molecule, mutant Q1140E also converted Stevioside mainly into one mono-α-glucosylated product. Hence, in one embodiment the mutant enzyme comprises the mutation L981A and/or W1065L, W1065E, W1065Q, W1065F.
- Also provided herein is the use of glucansucrase GTF180 of Lactobacillus reuteri strain 180 or a mutant thereof having the desired transglycosylation activity to enhance or improve the organoleptic properties of a steviol glycoside, for example to fully enhance the sweetness, partially remove the bitter taste and/or aftertaste of a steviol glycoside, preferably of Rebaudioside A or Stevioside.
- In the screening of substitution mutants useful for modifying Rebaudioside A, it was observed that the reaction mixture comprising an inactive mutant or enzyme that is unable to α-glucosylate Rebaudioside A turned cloudy due to the gradual precipitation of Rebaudioside A in time, whereas those comprising an active enzyme able to α-glucosylate Rebaudioside A remained clear. Without wishing to be bound by theory, the addition of glucose moieties to Rebaudioside A increases its solubility. This phenomenon allows the rapid selection of active mutants by evaluating the appearance of the reaction mixture, preferably after ˜6 hours of incubation in case of a final Rebaudioside A concentration at a minimum of 50 mM and ˜16 hours of incubation in case of a final Rebaudioside A concentration at a minimum of 30 mM. For example, when the reactions are performed in a microtiter plate or other type of transparent container, a mere visual inspection can be sufficient to identify one or more mutants for further characterization. Accordingly, the invention also provides a method for identifying a glucansucrase capable of modifying a steviol glycoside, preferably Rebaudioside A or Stevioside, comprising the steps of:
- a) generating a panel of mutants of GTF180 of Lactobacillus reuteri strain 180;
- b) incubating each mutant with a steviol glycoside in the presence of a glucose donor in an aqueous reaction mixture under conditions allowing for glycosylation of the steviol glycoside; and
- c) selecting at least one mutant of GTF180 of Lactobacillus reuteri 180 capable of modifying the steviol glycoside, by determining its capacity to at least partially prevent the reaction mixture from becoming cloudy;
- d) optionally further determining the structure of the modified steviol glycoside and selecting a mutant GTF180 of Lactobacillus reuteri 180 capable of modifying the C-19 site of the steviol glycoside.
- Preferably, the mutant panel is prepared starting from a truncated GTF180 enzyme, like the truncated variant lacking the N-terminal variable domain (GTF180-ΔN), and/or the N- and C-terminal domain V fragments (GTF180-ΔNΔV).
- In one embodiment, the panel of mutants comprises different substitution mutants, preferably non-conservative substitution mutants. For example, the screening method comprises creating a panel of GTF180 (truncation) mutants with different (non-conservative) amino acid substitutions at the Q1140 position and testing all the Q1140 mutants for steviol glycoside α-glucosylation. See
FIG. 8 herein below. - A further aspect of the invention relates to a modified steviol glycoside obtainable by a method according to the invention. In one embodiment, the steviol glycoside is modified with at least one glucose residue. In a specific aspect, the modification involves the addition of one glucose via an (α1-6) glycosidic bond (P-isomaltose) (
FIG. 5A ). In another specific aspect, the modification involves the addition of a glucosyl-glucose unit via an (α1→6) glycosidic bond at the β-linked glucose. Within the unit, the glucose residues can be connected via an (α1→6) glycosidic bond (isomaltose) or an (α1→3) glycosidic bond (nigerose) (FIGS. 5B and 5C ). - The invention preferably provides a steviol glycoside modified at the C-19 site of the steviol glycoside. More preferably, the modified steviol glycoside is only modified at the C-19 site of the steviol glycoside. For example, in one embodiment the invention provides a modified steviol glycoside which is only modified with a single α-glucose residue at the C-19 site of the steviol glycoside. In one embodiment, the C-19 site is modified with a single (α1→6) linked glucose.
- An exemplary modified steviol glycoside of the invention is selected from the group consisting of
- (i) 13-({β-D-glucopyranosyl-(1→2)-[8-D-glucopyranosyl-(1→3)-]β-D-glucopyranosyl}oxy)ent-kaur-16-en-19-oic acid α-D-glucopyranosyl-(1→6)-8-D-glucopyranosyl ester (
FIG. 5A ) - (ii) 13-({β-D-glucopyranosyl-(1→2)-[β-D-glucopyranosyl-(1→3)-]β-D-glucopyranosyl}oxy)ent-kaur-16-en-19-oic acid α-D-glucopyranosyl-(1-6)-α-D-glucopyranosyl-(1→6)-8-D-glucopyranosyl ester (
FIG. 5B ) - (iii) 13-({β-D-glucopyranosyl-(1→2)-[8-D-glucopyranosyl-(1→3)-]β-D-glucopyranosyl}oxy)ent-kaur-16-en-19-oic acid α-D-glucopyranosyl-(1→3)-α-D-glucopyranosyl-(1→6)-8-D-glucopyranosyl ester (
FIG. 5C ) - To determine the effect of (α1→6) glucosylation at the 19-O-glucosyl moiety of Rebaudioside A on sweetness and bitterness of Rebaudioside A, a taste evaluation was performed in which one of the novel Rebaudioside A glucosides, i.e. (i) 13-({f-D-glucopyranosyl-(1→2)-[8-D-glucopyranosyl-(1→3)-]β-D-glucopyranosyl}oxy)ent-kaur-16-en-19-oic acid α-D-glucopyranosyl-(1→6)-8-D-glucopyranosyl ester, was compared to Rebaudioside A. For this, in a blind test, twelve test persons that were able to perceive the bitter aftertaste of steviol glycosides were asked to rate sweetness and bitterness on a scale from 0 to 5, scoring 0 indicating not sweet/not bitter and 5 indicating very sweet/very bitter. A clear trend was observed showing that the novel Rebaudioside A glucoside had an increased and more natural sweetness and reduced bitterness compared to Rebaudioside A (
FIG. 7 ). - Also provided is the use of a modified steviol glycoside according to the invention as low-glycemic sweetener, and a method for sweetening a consumable, comprising including in said consumable an effective amount of the modified steviol glycoside, optionally combined with other edible ingredient, sweetener and/or sweetness enhancer.
- A further aspect relates to a sweetening composition comprising at least one modified steviol glycoside as provided herein. In certain embodiments the sweetener composition is a table top sweetener suitable to be used in cooking or to be added by a consumer to a beverage or other food. Such sweetener composition can be packaged and sold in bulk. Alternatively, in certain embodiments the sweetener composition is packaged in single serving packets to be opened at the time of use by the consumer. The at least one other edible ingredient of the sweetener composition, in accordance with certain embodiments, may, for example, be a flavorant, e.g., flavorant below, at or barely above its threshold perception level or in an amount readily perceptible to the consumer, a flowing agent, a coloring agent, a bulking agent to provide ease of handling and/or improved mouthfeel in beverages and other food products in which the sweetener composition is used, and/or other suitable ingredient, or a combination of any two or more of them. In certain embodiments the bulking agent(s) can provide an improved sweetness profile by increasing the up-front sweetness provided by the sweetener composition. In certain embodiments the at least one other edible ingredient is erythritol, D-tagatose, and/or D-psicose, for example a combination of two or more of those ingredients is included in the sweetener composition, such as erythritol and D-tagatose, or erythritol and D-psicose, or D-tagatose and D-psicose.
- Also provided is a consumable comprising at least one modified steviol glycoside according to the invention, optionally combined with another sweetener and/or sweetness enhancer. For example, the consumable is selected from the group of beverages, foodstuff, an oral care product, a tobacco product, a pharmaceutical products and nutraceutical products.
- Typically, a foodstuff comprises a sweetening amount of a modified steviol glycoside of the invention, and at least one other food ingredient. As used herein, the term “food ingredient” means any edible substance suitable to provide flavor, nutrition, color, bulk, texture or other mouthfeel, stability, acidity, thickening, anti-caking or the like, or a combination of any two or more of these. As further discussed below, exemplary food ingredients suitable for use in the novel food products disclose here include grain components, carbonated or non-carbonated water, other sweeteners, e.g., a sweetening amount of at least one nutritional sweetener, flavorants, acidulants, colorants, bulking agents, etc. In certain exemplary (i.e., non-limiting) embodiments, the food product is packaged in a single serving quantity. The food products of this aspect of the disclosure include, for example, solid foods, gels, beverages, etc.
- Examples of suitable sweeteners and sweetness enhancers include sucrose, fructose, glucose, high fructose corn syrup, corn syrup, xylose, arabinose, rhamnose, erythritol, xylitol, mannitol, sorbitol, inositol, acesulfame potassium, aspartame, neotame, sucralose, and saccharine, and mixtures thereof; trilobatin, hesperetin dihydrochalcone glucoside, naringin dihydrochalcone, mogrosides including mogroside V, Luo Han Guo extract, rubusoside, rubus extract, glycyphyllin, isomogroside V, mogroside IV, siamenoside I, neomogroside, mukurozioside lib, (+)-hernandulcin, 4β-hydroxyhemandulcin, baiyunoside, phlomisoside I, bryodulcoside, bryoside bryonoside, abrusosides A-E, cyclocarioside A, cyclocaryoside I, albiziasaponins A-E, glycyrrhizin, araboglycyrrhizin, periandrins I-V, pterocaryosides A and B, osladin, polypodosides A and B, telosmoside A8-18, phyllodulcin, huangqioside E neoastilbin, monatin, 3-acetoxy-5,7-dihydroxy-4′-methoxyflavanone, 2R,3R-(+)-3-Acetoxy-5,7,4′-trihydroxyflavanone, (2R.3R)-dihydroquercetin 3-O-acetate, dihydroquercetin 3-O-acetate 4-methyl ether, brazzein, curculin, mabinlin, monellin, neoculin, pentadin, thaumatin, and combinations thereof. Some of the compounds listed above are known sweetness enhancers as well as sweeteners. When used as sweetness enhancers they are normally used below their sweetness detection thresholds.
- The beverages include, for example, juice beverages (e.g., beverages comprising one or more fruit juices and/or one or more vegetable juices), hydration beverages, carbonated soft drinks (CSDs), frozen beverages, frozen carbonated beverages, diet or other reduced calorie beverages, etc. It will be recognized by those skilled in the art that there is overlap between these categories. As used herein, “reduced calorie beverage” means a beverage having at least a 25% reduction in calories per 8 oz. serving of beverage as compared to the full calorie version, typically a previously commercialized full-calorie version (e.g., wherein substantially all of the sweetening comes from a nutritive sweetener, such as sucrose, HFCS or the like). In at least certain embodiments, a reduced calorie beverage has about a 50% reduction in calories per 8 oz. serving as compared to the full calorie version. As used herein, a “low-calorie beverage” has fewer than 40 calories per 8 oz. serving of beverage. As used herein, “zero-calorie” or “diet” means having less than 5 calories per serving, e.g., per 8 oz. for beverages.
- According to another aspect, beverage products are provided that comprises water, and acidulant component comprising at least one acid, a flavoring component comprising at least one flavoring ingredient, and a sweetener component comprising a sweetening amount of modified steviol glucoside, and optionally a sweetening amount of one or more other sweeteners. In certain exemplary embodiments of the beverage products according to this aspect, the beverage products are ready-to-drink beverages having a pH higher than 3.0 and lower than 4.0. Such ready-to-drink beverages may, for example, be hydration beverages, also referred to as sports drinks, having added electrolytes. In other exemplary embodiments the ready-to-drink beverages are carbonated soft drinks, for example reduced calorie or diet cola beverages. In certain exemplary embodiments of the beverage products according to this aspect, the beverage products are syrups suitable to be diluted, for example, by a 1-plus-5 throw with carbonated or un-carbonated water to produce a ready-to-drink beverage.
- According to certain embodiments, the modified steviol glycoside of the invention provides at least 10% of the total sweetening of the consumable, e.g. a diet cola syrup, a ready-to-drink diet cola beverage, another beverage product, or another food product in accordance with the present disclosure. According to certain embodiments, it provides at least 20% of the total sweetening, or at least 30% of the total sweetening, or at least 40% of the total sweetening, or at least half of the total sweetening, or at least 60% of the total sweetening, or at least 70% of the total sweetening, or at least 80% of the total sweetening, or at least 90% of the total sweetening. Optionally every additional sweetener ingredient is an organic sweetener. Optionally every sweetener ingredient is a natural sweetener.
- Optionally every sweetener ingredient is a steviol glycoside. Optionally every ingredient is an organic and/or natural ingredient, such that the reduced calorie (e.g., diet) carbonated cola beverage product is correspondingly an organic and/or natural beverage product.
- Preferably, the consumable comprises at least one modified Rebaudioside A selected from those represented in
FIG. 5 . - For example, a beverage may comprise modified Rebaudioside A in concentrations of about 30 ppm-about 750 ppm (e.g. from about 50 ppm up to 350 ppm). However the amount added mainly depends on the level of sweetness desired and may depend on the presence of other ingredients. For example, fruit juice comprises sugar and thus contributes to the level of sweetness. In one embodiment, the modified Rebaudioside A is the only sweetener added to the flavored beverage. In another embodiment, modified Rebaudioside A may be combined with other sweetener and/or sweetness enhancers. In a preferred embodiment, the modified Rebaudioside A is combined with a mogroside, like mogroside V.
-
FIG. 1 . Chemical structures of Stevioside, Rebaudioside A and B, and Steviolbioside. [Glc1], etc. denotation of glucose residues for NMR assignment. -
FIG. 2A-C . Effect of Rebaudioside A and sucrose concentrations on the transglucosylation (solid bars) and hydrolysis (hatched bars) activity using 0.12 mg/mL purified enzyme: (A) GTF180-ΔN, (B) GTF180-ΔN mutant 51137Y and (C) GTF180-ΔN mutant Q1140E. -
FIG. 3 . NP-HPLC product profiles of a 4 hour incubation of 10 U/mL GTF180-ΔN(WT), mutant S1137Y and mutant Q1140E with 50 mM Rebaudioside A(*) and 1 M sucrose (**=RebAG1). -
FIG. 4A-C . Time course of Rebaudioside A utilization (dashed line) and RebAG1 formation by α-glucosylation (solid line) using 10 U/mL enzyme: (A) GTF180-ΔN, (B) GTF180-ΔN mutant S1137Y and (C) GTF180-ΔN mutant Q1140E, showing 55%, 73% and 96% conversion, respectively. -
FIG. 5A-D . Structures of modified Rebaudioside A glucosides produced by GTF180-ΔN and mutants GTF180-ΔN S1137Y and GTF180-ΔN Q1140E: (A) RebAG1=13-({β-D-glucopyranosyl-(1→2)-[β-D-glucopyranosyl-(1→3)-]β-D-glucopyranosyl}oxy)ent-kaur-16-en-19-oic acid α-D-glucopyranosyl-(1→6)-β-D-glucopyranosyl ester (B) 13-({β-D-glucopyranosyl-(1→2)-[β-D-glucopyranosyl-(1→3)-]β-D-glucopyranosyl}oxy)ent-kaur-16-en-19-oic acid α-D-glucopyranosyl-(1-6)-α-D-glucopyranosyl-(1→6)-β-D-glucopyranosyl ester (C) 13-({f-D-glucopyranosyl-(1→2)-[β-D-glucopyranosyl-(1→3)-]β-D-glucopyranosyl}oxy)ent-kaur-16-en-19-oic acid α-D-glucopyranosyl-(1→3)-α-D-glucopyranosyl-(1→6)-β-D-glucopyranosyl ester (D) The 500-MHz 1H NMR spectra of RebAG1 product of GTF180-ΔN (a) and mutants Q1140E (b) and S1137Y (c) recorded in D2O at 334K. -
FIG. 6 . TLC analysis of products obtained in a 1 hour incubation of 50 mM Stevioside and 50 mM Rebaudioside A with 100 mM sucrose with and without 20 U/ml Q1140E, before and after alkaline saponification with 1 M NaOH. -
FIG. 7 . Sensory evaluation (n=12) of several sweeteners: Stevioside (250 mg/L), Rebaudioside A (300 mg/L), RebAG1 (350 mg/mL), and sucrose (60 g/L). Evaluated taste attributes were sweetness (hatched bars) and bitterness (solid bars).Score 0=not sweet/not bitter,score 5=very sweet/very bitter. -
FIG. 8 . TLC analysis of products obtained in a 2 hour incubation of 50 mM Rebaudioside A and 200 mM sucrose with GTF180-ΔNΔV (Q), GTF180-ΔNΔV Q1140 amino acid substitution mutants Q1140 G/S/I/V/W/D/M/C/E/L/K/T/P/R/F/N/Y, or GTF180-ΔN Q1140E (E*). -
FIG. 9A-C . Amino acid sequence of glucansucrase GTF180 from Lactobacillus reuteri 180. Panel (A) full length protein; panel (B)N-terminally truncated mutant GTF180-ΔN; panel (C)N-terminally truncated and domain V truncated mutant GTF180-ΔNΔV. - The section below exemplifies the advantageous use of glucansucrase GTF180-ΔN of Lactobacillus reuteri strain 180 and its derived single amino acid substitution mutants to α-glucosylate Rebaudioside A. GTF180-ΔN and derived mutant enzymes glucosylate Rebaudioside A specifically at the C-19 site, introducing (α1→6) and (α1→3) glycosidic linkages, which are resistant to hydrolysis by the amylolytic enzymes present in saliva. Several GTF180-ΔN mutants displayed a much higher transglucosylating activity towards Rebaudioside A than GTF180-ΔN. Interestingly, one mutant, Q1140E, showed nearly 100% conversion of Rebaudioside A and attached mostly a single (α1→6)-glucose at the C-19 site of Rebaudioside A.
- The produced novel Rebaudioside A glucosides are very interesting, carrying one and two (α1→6)-linked glucose units specifically at the C-19 β-linked glucose. The mono-α-glucosylated Rebaudioside A product, RebAG1, has an increased and more natural sweetness and reduced bitterness compared to Rebaudioside A. These improved novel steviol glycosides of the invention are of great interest as functional food ingredients.
- Rebaudioside A (2) and Stevioside (1) were purchased from Sigma Aldrich.
- All glucansucrase and fructansucrase enzymes were produced as described by Meng et al (2014) and purified as described by Kralj et al (2004b). GTF180-ΔN is the 117 kDa N-terminally truncated (741 residues) fragment of the GTF180 full-length protein (Kralj et al. 2004a). The construction of truncation mutant GTF180-ΔNΔV, consisting of amino acids 794-1636 of the GTF180 enzyme is described in Meng et al. (2015a). GTF180-ΔN mutant enzymes were created by van Leeuwen et al. (2009), Meng et al. (2015a), and Meng et al. (2015b). Amino acid substitutions in truncation mutant GTF180-ΔNΔV were created as described by Meng et al. (2015b)
- Enzyme activity assays were performed at 100 mM and 1000 mM sucrose, with and without 50 mM Rebaudioside A in 25 mM sodium acetate (pH 4.7); 1 mM CaCl2); and 0.12 mg/mL purified GTF180-ΔN enzyme or GTF180-ΔN mutant enzyme at 37° C. Samples of 100 μL were taken every 30 sec for 4 min and the reaction was immediately stopped by incubating with 20 μL 1000 mM NaOH for 30 min. The inactivated samples were diluted two times in deionized water and from 10 μL of the diluted sample the glucose and fructose concentrations were determined enzymatically by monitoring the reduction of NADP with the hexokinase and glucose-6-phosphate dehydrogenase/phosphoglucose isomerase assay (Roche) as described previously (Mayer 1987). Quantitative determination of the release of glucose and fructose from sucrose allowed estimation of the activities of the glucansucrase enzymes (van Geel-Schutten et al. 1999). Fructose release corresponds to the total enzyme activity and glucose release to the hydrolytic activity. The transglycosylation activity can be obtained by subtracting the hydrolytic activity from the total activity. One unit (U) of enzyme is defined as the amount of enzyme required for producing 1 μmol monosaccharide per min in a reaction mixture containing 25 mM sodium acetate (pH 4.7); 1 mM CaCl2; and 1000 mM sucrose at 37° C.
- Incubation reactions were performed in 25 mM sodium acetate (pH 4.7), 1 mM CaCl2), 50 to 1,000 mM sucrose, 50-100 mM steviol glycoside, and 2-30 U/mL purified GTF180-ΔN enzyme or GTF180-ΔN mutant enzyme at 37° C. for 15 min to 24 hours. Reactions were stopped by heat inactivation (100° C. for 15 min). From the
inactivated samples 250 uL was mixed with 1000 ul of 10 mM catechol (internal standard) and subsequently purified by solid phase extraction using Strata-X 33u Polymeric Reversed Phase columns (Phenomenex). ForHPLC analysis 20 μL of the purified sample was injected on aLuna 10 μm NH2 chromatography column (250 mm×4.6 mm; Phenomenex). Reaction components were separated at a flow-rate of 1 mL/min under gradient elution conditions, starting with a 2 min isocratic step of 70% solvent A followed by a linear gradient from 70 to 55% solvent A over 9 min (solvent A=acetonitrile; solvent B=0.025% acetic acid). Rebaudioside A and the mono-α-glucosylated Rebaudioside A product concentrations were determined with NP-HPLC, using their corresponding calibration curves ranging from 1.56 to 50 mM. All data were normalized with catechol as internal standard. The standard deviation of the response was less than 5%. All NP-HPLC analyses were performed on an UltiMate 3000 chromatography system (ThermoFischer Scientific, Amsterdam, The Netherlands), equipped with an Endurance autosampler (Spark Holland, The Netherlands). - For quantitative synthesis of α-glucosylated Rebaudioside A products using GTF180-ΔN and its derived mutants, incubations were performed in 5 mL 25 mM sodium acetate (pH 4.7), 1 mM CaCl2), 50 mM steviol glycoside with two batches of 1,000 mM equivalent of sucrose donor (t=0 and 3 h) to a total of 2,000 mM sucrose, using 10 U/mL enzyme at 37° C. for 24 hours. Products were purified from the incubation mixture by solid phase extraction using Strata-X 33u Polymeric Reversed Phase columns (Phenomenex). Products were separated on a
Luna 10 μm NH2 semi-preparative chromatography column (250 mm×10 mm, Phenomenex) and were manually collected at a flow-rate of 4.6 mL/min, starting with a 2 min isocratic step of 80% solvent A followed by a linear gradient of 80 to 50% solvent A over 38 min (solvent A=acetonitrile; solvent B=0.025% acetic acid). The solvent of the collected fractions was evaporated under a stream of nitrogen gas and the dried materials were dissolved in deionized water. - Samples were spotted on TLC sheets (
Merck Kieselgel 60 F254, 20×20 cm), which were developed with n-butanol:acetic acid:water=2:1:1. Spots were visualized by orcinol/sulfuric acid staining and compared with a simultaneous run of standard compounds. - To release the 19-O-linked glycosyl moiety, 4 mg of each steviol glycoside product was dissolved in 1 M NaOH (1 mL) and heated at 80° C. for 2.5 h.
- Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS) experiments were performed using an Axima™ mass spectrometer (Shimadzu Kratos Inc., Manchester, UK) equipped with a Nitrogen laser (337 nm, 3 ns pulse width). Positive-ion mode spectra were recorded using the reflector mode at a resolution of 5000 FWHM and delayed extraction (450 ns). Accelerating voltage was 19 kV with a grid voltage of 75.2%. The mirror voltage ratio was 1.12 and the acquisition mass range was 200-6000 Da. Samples were prepared by mixing 1 μL sample solutions with 1 μL 10% 2,5-dihydroxybenzoic acid in 70% ACN as matrix solution.
- Resolution-enhanced 1D/2D 500-MHz 1H NMR spectra were recorded in D2O on a Bruker DRX-500 spectrometer (Bijvoet Center, Department of NMR Spectroscopy, Utrecht University) at a probe temperature of 334K. Data acquisition and processing were done with Bruker Topspin 2.1. Prior to analysis, samples were exchanged twice in D2O (99.9 atom % D, Cambridge Isotope Laboratories, Inc., Andover, Mass.) with intermediate lyophilization, and then dissolved in 0.6 mL D2O. Suppression of the deuterated water signal (HOD at 4.40 ppm) was achieved by applying a WEFT (water eliminated Fourier transform) pulse sequence for 1D NMR experiments and by a pre-saturation of 1 s during the relaxation delay in 2D experiments. The 2D TOCSY spectra were recorded using an MLEV-17 (composite pulse devised by Levitt et al (1982)) mixing sequence with spin-lock times of 40-200 ms. The 2D ROESY spectra were recorded using standard Bruker XWINNMR software with mixing time of 200 ms. The carrier frequency was set at the downfield edge of the spectrum in order to minimize TOCSY transfer during spin-locking. Natural abundance 2D 13C-1H HSQC experiments (1H frequency 500.0821 MHz, 13C frequency 125.7552 MHz) were recorded without decoupling during acquisition of the 1H FID. Resolution enhancement of the spectra was performed by a Lorentzian-to-Gaussian transformation for 1D spectra or by multiplication with a squared-bell function phase shifted by π/(2.3) for 2D spectra, and when necessary, a fifth order polynomial baseline correction was performed. Chemical shifts (δ) are expressed in ppm by reference to internal acetone (δ 2.225 for 1H and δ 31.07 for 13C)
- Taste evaluations were performed in which novel α-glucosylated products of Rebaudioside A (350 mg/L) were compared to sucrose (60 g/L), Rebaudioside A (300 mg/L), and stevioside (250 mg/L). In a blind test, twelve test persons that were able to perceive the bitter aftertaste of steviol glycosides were asked to rate sweetness and bitterness on a scale from 0 to 5, with 0 indicating not sweet/not bitter and 5 indicating very sweet/very bitter.
- Over a hundred glucan and fructansucrase wild type and mutant enzymes, mostly from Lactobacillus reuteri, were screened for Rebaudioside A α-glucosylation. For this, enzymes were incubated in 50 mM Rebaudioside A (
FIG. 1 ) and 1000 mM sucrose for 3 hours. HPLC and TLC analysis of the reaction mixtures showed that only GTF180-ΔN enzyme and mutant enzymes of GTF180-ΔN were able to glucosylate Rebaudioside A (Table 1). Interestingly, two single GTF180-ΔN mutants S1137Y and Q1140E, which are single amino acid substitutions close to the transition state stabilizing residue D1136 (van Leeuwen et al. 2009) displayed much better transglucosylating activity towards Rebaudioside A than GTF180-ΔN. Also GTF180-ΔN mutants L981A and W1065L (Meng et al. 2015b) were able to a-glucosylate Rebaudioside A (Table 1), but showed almost no polymerization (i.e. oligosaccharide and glucan formation from sucrose) activity (data not shown). This is a clear advantage during downstream processing, the purification of the α-glucosylated Rebaudioside A products from mono- and disaccharides, oligosaccharides and glucans. By eliminating α-glucan synthesis, the most important side reaction, higher glycosylation yields were obtained for Rebaudioside A. At lower sucrose concentration (200 mM), these mutants had similar or even higher transglucosylating activity with Rebaudioside A than GTF180-ΔN and mutants S1137Y and Q1140E (data not shown). -
TABLE 1 Overview of the Rebaudioside A α-glucosylation potential of glucansucrase and fructansucrase enzymes from various Lactobacillus strains. Activity Enzyme Mutation *Glp (1→ →3)Glp (→ →4)Glp (→ →6)Glp (→ →3,6)Glp (→ on RebA GTF180-ΔNa N-terminal truncated 12 24 52 12 + GTF180a (**AY697430); Met-Gly-742-1772-His6 GTF180-ΔNΔVb domain V deletion mutant of 12 23 52 13 + GTF180-ΔN; Met-794-1636-His6 GTF180-ΔN-PNNSc triple amino acid mutant 18 10 12 42 18 + (V1027P: S1137N: A1139S) of GTF180-ΔN GTF180-ΔN-SNAEd single amino acid mutant 12 16 2 52 18 ++++++ (Q1140E) of GTF180-ΔN GTF180-ΔN-SNAAd single amino acid mutant 11 6 69 14 +/− (Q1140A) of GTF180-ΔN GTF180-ΔN-SNAHd single amino acid mutant 8 8 76 8 +/− (Q1140H) of GTF180-ΔN GTF180-ΔN-NNAd single amino acid mutant 12 26 3 47 12 ++ (S1137N) of GTF180-ΔN GTF180-ΔN-YDAd double amino acid mutant 19 23 7 31 20 ++++ (S1137Y: N1138D) of GTF180-ΔN GTF180-ΔN-YNAd single amino acid mutant 18 21 4 39 18 ++++ (S1137Y) of GTF180-ΔN GTF180-ΔN-SDAd single amino acid mutant 10 24 56 10 + (N1138D) of GTF180-ΔN GTF180-ΔN-XM1e single amino acid mutant ++ (L981A) of GTF180-ΔN GTF180-ΔN-XM2e single amino acid mutant ++ (W1065L) of GTF180-ΔN GTFA-ΔNf N-terminal truncated 9 46 34 12*** −**** GTFA (AX306822)g GTFA-ΔN N1134Sh single amino acid mutant 8 12 76 4*** − (N1134S) of GTFA-ΔN GTFA-ΔN N1134Eh single amino acid mutant 8 49 36 7*** − (N1134E) of GTFA-ΔN GTFA-ΔN N1134Ah single amino acid mutant 13 25 49 13*** − (N1134A) of GTFA-ΔN GTFA-ΔN NEVh double amino acid mutant 10 49 29 12*** − (N1135E: S1136V) of GTFA-ΔN GTFBa wild type (AY697435) − GTFMLIa N-terminal truncated 47 10 26*** − GTFMLI (AY697431)a GTFOi N-terminal truncated 67 13 15 − GTFO (AY911856)i InuJj N-terminal truncated − InuJj fructansucrase InuGA-RMk wild type fructansucrase − InuGB-Rk wild type fructansucrase − LevG-Rk wild type fructansucrase − aKralj et al (2004a); bMeng et al (2015a); cVan Leeuwen et al (2008); dVan Leeuwen et al (2009); eMeng et al. (2015b); fKralj et al (2004b); gKralj et al (2002); hKralj et al (2006); iKralj et al (2005); jAnwar et al (2008); kAnwar et al (2010); *linkage distribution; **Genbank accession number; ***→4,6)Glp (→; ****not active on Rebaudioside A (RebA) - To optimize the reaction conditions towards glucosylation of Rebaudioside A the effect of Rebaudioside A and sucrose on the transglucosylation activity of GTF180-ΔN and mutants S1137Y and Q1140E was determined. For this, enzyme activity assays were performed at 100 mM and 1000 mM sucrose with and without 50 mM Rebaudioside A. All three enzymes were more hydrolytic at low sucrose concentrations (
FIG. 2 ). Both mutant enzymes were almost completely hydrolytic at 100 mM sucrose. However, when 50 mM Rebaudioside A was added to the reaction or when the sucrose concentration was increased to 1000 mM, the transglucosylation activity of all three enzymes was noticeably increased, showing the highest overall activity and highest transglucosylation to hydrolysis ratio at 1 M sucrose and 50 mM Rebaudioside A. These reaction conditions were used to follow the α-glucosylation of Rebaudioside A by GTF180-ΔN and mutants S1137Y and Q1140E in more detail. - When 50 mM Rebaudioside A, 1000 mM sucrose, and 10 U/mL enzyme was used, mutants S1137Y and Q1140E glucosylated respectively ˜73% and ˜96% Rebaudioside A compared to ˜55% by GTF180-ΔN (
FIG. 4 ). To our surprise, mutant Q1140E mainly produced mono-glucosylated Rebaudioside A (RebAG1), yielding ˜35 mM RebAG1 from 50 mM Rebaudioside A (FIG. 3 andFIG. 4 ). Mutant S1137Y produced a similar amount of RebAG1 as the GTF180-ΔN enzyme (˜13 mM) (FIG. 3 ), but synthesized a higher amount of multiple glycosides (FIG. 3 ). - From all the tested glucan- and fructansucrase enzymes, mutant GTF180-ΔN Q1140E showed the highest Rebaudioside A glucosylation activity and displayed mainly mono-glucosylation of Rebaudioside A. Therefore, besides mutations Q1140 E/A/H also additional amino acid substitutions at position Q1140 were created in mutant GTF180-ΔNΔV and tested for Rebaudioside A glucosylation (
FIG. 8 ). For this, 1 mg/ml of the enzymes was incubated for 2 hours at 37° C. with 50 mM Rebaudioside A and 200 mM sucrose in buffer (25 mM sodium acetate (pH 4.7), 1 mM CaCl2). The incubation mixtures were analyzed by TLC (FIG. 8 ). Under these conditions, several Q1140 substitution mutants (for e.g. Q1140 F/N/Y) showed even a higher Rebaudioside A glucosylation than mutant Q1140E, although the latter one still had the highest mono-glucosylation yield. Some mutations (for e.g. Q1140D) had a slightly negative effect on Rebaudioside A glucosylation. Interestingly, mutant Q1140R showed almost no activity on sucrose, although Rebaudioside A glucosylation was hardly affected by the mutation. It appears that the sucrose was mainly used for glucosylation of Rebaudioside A and not for side reactions, such as oligosaccharide formation. - Looking at the molecular structure of Rebaudioside A (
FIG. 1 ), there are four Glcp residues (Glc1, Glc2, Glc3 and Glc4) with a total of 14 free hydroxyl groups, which can act as acceptors for transglucosylation. - GTF180-ΔN converts sucrose into oligo- and polysaccharides, catalyzing the transglucosylation of Glcp residues in (α1→3)- and (α1→6)-linkages (van Leeuwen et al. 2008), there are 3 potential (1→3) sites and 4 potential (1→6) sites present at Rebaudioside A for the first attachment of a Glc residue.
- In order to isolate α-glucosylated products of Rebaudioside A glucosides for structural characterization, incubations were done with 10 U/mL enzyme with 50 mM Rebaudioside A and 1000 mM sucrose. After 3 hours 1000 mM extra sucrose was added to the reaction mixtures and incubated for an additional 21 hours. Glucosides were isolated from the reaction mixtures using semi-preparative NP-HPLC. Interestingly, NMR structural analysis and methylation analysis of the mono-α-glucosylated product showed that GTF180-ΔN and mutants S1137Y and Q1140E specifically and only glucosylated Rebaudioside A at the C-19-linked glucose, attaching an (α1→6)-linked glucose (100%), yielding RebAG1 (see also
FIG. 5A ). - The di-glucosylated Rebaudioside A products of GTF180-ΔN and mutant S1137Y were both linear elongations of the structure of RebAG1 with an (α1→3)-linked glucose (˜75%) (
FIG. 5C ) or another (α1→6)-linked glucose (˜25%) (FIG. 5B ).FIG. 5D panels (a), (b) and (c) show the 500-MHz 1H NMR spectra of RebAG1 produced by, respectively, GTF180-ΔN, GTF180-ΔN Q1140E and GTF180-ΔN S1137Y. - To confirm that introduction of extra Glcp residues via transglucosylation by GTF180-ΔN only occurred on the C-19 β-glucosyl moiety of Rebaudioside A, the isolated fractions were subjected to an alkaline saponification to specifically hydrolyze the 19-carboxyl-glucosyl ester bound (
FIG. 1 andFIG. 6 ). Identical products were obtained from Rebaudioside A and the α-glucosylated products of Rebaudioside A, according to TLC, MALDI-TOF-MS (m/z 826 [M+H]+) and NMR spectroscopy, being Rebaudioside A missing the complete glucosyl moiety at C-19. The resultant structure is known as Rebaudioside B (3) (FIG. 1 ). - For commercial purposes it may be desirable to improve sweetness and decrease bitterness of the whole steviol glycoside leave extract. Since Stevioside (˜5-10% w/w of dried leaves) is the most abundant and one of the most bitter tasting steviol glycosides, our aim was also to enhance the taste profile of Stevioside. Therefore, glucosylation reactions were also performed with GTF180-ΔN and substitution mutants derived thereof with Stevioside as the acceptor molecule. All three enzymes were also able to α-glucosylate stevioside. As observed with Rebaudioside A as acceptor molecule, mutant Q1140E converted Stevioside mainly into a single mono-α-glucosylated product (data not shown). In order to determine whether GTF180-ΔN mutant Q1140E glucosylates Stevioside also specifically at the C-19 site, steviol glucosides produced by Q1140E were subjected to alkaline saponification of the 19-carboxyl-glucosyl ester linkage with 1 M NaOH, to specifically remove the C-19 moiety. If alkaline saponification of the Q1140E steviol glucosides yields Steviolbioside (4)(
FIG. 1 ) (i.e. Stevioside minus the C-19 moiety), then glucosylation occurred specifically at the C-19 site of Stevioside. On TLC plates multiple steviol glucosides were visible in the 1 hour incubation of Stevioside with Q1140E (FIG. 6 ). However, only one spot was observed when the incubation mixture was treated with 1 M NaOH and it migrated at the same height as the product formed after saponification of the Stevioside positive control. With MALDI-TOF analysis a molecular mass of 665.59 was detected, corresponding with the sodium-adduct of Steviolbioside. These results show that GTF180-ΔN Q1140E also specifically α-glucosylates Stevioside at the C-19 β-linked glucosyl moiety. - To determine the effect of (α1→6) glucosylation at the 19-O-glucosyl moiety of Rebaudioside A on sweetness and bitterness, a taste evaluation was performed in which one the novel α-glucosylated products of Rebaudioside A, RebAG1, was compared to Rebaudioside A. For this, in a blind test, twelve test persons that were able to perceive the bitter aftertaste of steviol glycosides were asked to rate sweetness and bitterness on a scale from 0 to 5, with 0 indicating not sweet/not bitter and 5 indicating very sweet/very bitter. A clear trend was observed showing that the novel RebAG1 had an increased and a more natural sweetness and reduced bitterness compared to Rebaudioside A (
FIG. 7 ). -
- Brahmachari G, Mandal L C, Roy R, Mondal S, Brahmachari A K (2011) Stevioside and related compounds—molecules of pharmaceutical promise: a critical overview. Arch Pharm (Weinheim) 344:5-19. doi: 10.1002/ardp.201000181
- Brandle J E, Starratt ΔN, Gijzen M (1998) Stevia rebaudiana: Its agricultural, biological, and chemical properties. Can J plant Sci 78:527-536.
- Chatsudthipong V, Muanprasat C (2009) Stevioside and related compounds: therapeutic benefits beyond sweetness. Pharmacol Ther 121:41-54. doi: 10.1016/j.pharmthera.2008.09.007
- Ciucanu I, Kerek F (1984) A simple and rapid method for the permethylation of carbohydrates. Carbohydr Polym 131:209-217.
- Darise M, Mizutani K, Kasai R, Tanaka O (1984) Enzymic transglucosylation of rubusoside and the structure-sweetness relationship of steviol-bisglycosides. Agric Biol Chem 10:2483-2488. doi: 10.1080/00021369.1984.10866520
- DuBois G E, Dietrich P S, Lee J F, McGarraugh G V, Stephenson R A (1981) Diterpenoid sweeteners. Synthesis and sensory evaluation of stevioside analogues nondegradable to steviol. J Med Chem 24:1269-71.
- DuBois G E, Stephenson R A (1985) Diterpenoid sweeteners. Synthesis and sensory evaluation of stevioside analogues with improved organoleptic properties. J Med Chem 28:93-8.
- Fukunaga Y, Miyata T, Nakayasu N, Mizutani K, Kasai R, Tanaka O (1989) Enzymic transglucosylation products of stevioside: Separation and sweetness-evaluation. Agric Biol Chem 53:1603-1607. doi: 10.1271/bbb1961.53.1603
- Geuns J (2003) Stevioside. Phytochemistry 64:913-921. doi: 10.1016/S0031-9422(03)00426-6
- Goyal S K, Samsher, Goyal R K (2010) Stevia (Stevia rebaudiana) a bio-sweetener: a review. Int J Food Sci Nutr 61:1-10. doi: 10.3109/09637480903193049
- Hellfritsch C, Brockho A, Sta F, Meyerhof W, Hofmann T (2012) Human psychometric and taste receptor responses to steviol glycosides. J Agric Food Chem 60:6782-6793.
- Kamerling J P, Vliegenthart JFG (1989) Clinical Biochemistry—Principles, Methods, Applications. Walter de Gruyter, Berlin
- Kralj S, van Geel-Schutten G H, Dondorff M M G, Kirsanovs S, van der Maarel M J E C, Dijkhuizen L (2004a) Glucan synthesis in the genus Lactobacillus: isolation and characterization of glucansucrase genes, enzymes and glucan products from six different strains. Microbiol 150:3681-3690. doi: 10.1099/mic.0.27321-0
- Kralj S, van Geel-Schutten G H, van der Maarel M J E C, Dijkhuizen L (2004b) Biochemical and molecular characterization of
Lactobacillus reuteri 121 reuteransucrase. Microbiol 150:2099-2112. doi: 10.1099/mic.0.27105-0 - Leemhuis H, Pijning T, Dobruchowska J M, van Leeuwen S S, Kralj S, Dijkstra B W, Dijkhuizen L (2013) Glucansucrases: three-dimensional structures, reactions, mechanism, α-glucan analysis and their implications in biotechnology and food applications. J Biotechnol 163:250-272. doi: 10.1016/j.jbiotec.2012.06.037
- Lemus-Mondaca R, Vega-GAlvez A, Zura-Bravo L, Ah-Hen K (2012) Stevia rebaudiana Bertoni, source of a high-potency natural sweetener: A comprehensive review on the biochemical, nutritional and functional aspects. Food Chem 132:1121-1132. doi: 10.1016/j.foodchem.2011.11.140
- Levitt M H, Freeman R, Frenkiel T (1982) Broadband Heteronuclear Decoupling. J Magn Reson 47:328-330.
- Li S, Li W, Xiao Q, Xia Y (2013) Transglycosylation of stevioside to improve the edulcorant quality by lower substitution using cornstarch hydrolyzate and CGTase. Food Chem 138:2064-9. doi: 10.1016/j.foodchem.2012.10.124
- Lobov S V, Kasai R, Ohtani K, Yamasaki K (1991) Enzymic production of sweet stevioside derivatives: Transglucosylation by glucosidases. Agric Biol Chem 55:2959-2965.
- Madan S, Ahmad S, Singh G N, Kohli K, Kumar Y, Singh R, Garg M (2010) Stevia rebaudiana (Bert.) Bertoni—A review. Indian J Nat Prod Resour 1:267-286.
- Mayer R M (1987) Dextransucrase: a glucosyltransferase from Streptococcus sanguis. Methods Enzymol 138:649-661.
- Meng X, Dobruchowska J M, Pijning T, Gerwig G J, Kamerling J P, Dijkhuizen L (2015a) Truncation of domain V of the multidomain glucansucrase GTF180 of Lactobacillus reuteri 180 heavily impairs its polysaccharide-synthesizing ability. Appl Microbiol Biotechnol 5885-5894. doi: 10.1007/s00253-014-6361-8
- Meng X, Dobruchowska J M, Pijning T, Lopez C A, Kamerling J P, Dijkhuizen L (2014) Residue Leu940 has a crucial role in the linkage and reaction specificity of the glucansucrase GTF180 of the probiotic bacterium Lactobacillus reuteri 180. J Biol Chem 289:32773-32782. doi: 10.1074/jbc.M114.602524
- Meng X, Pijning T, Dobruchowska J M, Gerwig G J, Dijkhuizen L (2015b) Characterization of the functional roles of amino acid residues in acceptor binding subsite+1 in the active site of the glucansucrase GTF180 enzyme of Lactobacillus reuteri 180. J Biol Chem 290:30131-30141. doi: 10.1074/jbc.M115.687558
- Musa A, Gasmalla M A A, Miao M, Zhang T, Aboshora W, Eibaid A, Jiang B (2014) Separation and structural characterization of tri-glucosyl-stevioside. J Acad Ind Res 2:593-598.
- Prakash I, Markosyan A, Bunders C (2014) Development of Next Generation Stevia Sweetener: Rebaudioside M. Foods 3:162-175. doi: 10.3390/foods3010162
- Puri M, Sharma D, Tiwari A K (2011) Downstream processing of stevioside and its potential applications. Biotechnol Adv 29:781-91. doi: 10.1016/j.biotechadv.2011.06.006
- Shivanna N, Naika M, Khanum F, Kaul V K (2013) Antioxidant, anti-diabetic and renal protective properties of Stevia rebaudiana. J Diabetes Complications 27:103-13. doi: 10.1016/j.jdiacomp.2012.10.001
- van Geel-Schutten G H, Faber E J, Smit E, Bonting K, Smith M R, Ten Brink B, Kamerling J P, Vliegenthart JFG, Dijkhuizen L (1999) Biochemical and structural characterization of the glucan and fructan exopolysaccharides synthesized by the Lactobacillus reuteri wild-type strain and by mutant strains. Appl Environ Microbiol 65:3008-3014.
- van Leeuwen S S, Kralj S, Eeuwema W, Gerwig G J, Dijkhuizen L, Kamerling J P (2009) Structural characterization of bioengineered α-D-Glucans produced by mutant glucansucrase GTF180 enzymes of Lactobacillus reuteri strain 180. Biomacromolecules 10:580-588.
- van Leeuwen S S, Kralj S, van Geel-Schutten I H, Gerwig G J, Dijkhuizen L, Kamerling J P (2008) Structural analysis of the alpha-D-glucan (EPS180) produced by the Lactobacillus reuteri strain 180 glucansucrase GTF180 enzyme. Carbohydr Res 343:1237-50. doi: 10.1016/j.carres.2008.01.042
- Yadav S K, Guleria P (2012) Steviol glycosides from Stevia: biosynthesis pathway review and their application in foods and medicine. Crit Rev Food Sci Nutr 52:988-98. doi: 10.1080/10408398.2010.519447
- Ye F, Yang R, Hua X, Shen Q, Zhao W, Zhang W (2013) Modification of stevioside using transglucosylation activity of Bacillus amyloliquefaciens α-amylase to reduce its bitter aftertaste. LWT—Food Sci Technol 51:524-530. doi: 10.1016/j.lwt.2012.12.005
Claims (10)
1-12. (canceled)
13. A modified steviol glycoside obtainable by incubating a steviol glycoside substrate in the presence of sucrose as a glucose donor and the glucansucrase GTF180 of Lactobacillus reuteri strain 180, or a mutant thereof having the desired transglycosylation activity.
14. A modified steviol glycoside selected from the group consisting of
(i) 13-({β-D-glucopyranosyl-(1→2)-[β-D-glucopyranosyl-(1→3)-]β-D-glucopyranosyl}oxy)ent-kaur-16-en-19-oic acid α-D-glucopyranosyl-(1→6)-β-D-glucopyranosyl ester;
(ii) 13-({β-D-glucopyranosyl-(1→2)-[β-D-glucopyranosyl-(1→3)-]β-D-glucopyranosyl}oxy)ent-kaur-16-en-19-oic acid α-D-glucopyranosyl-(1→6)-α-D-glucopyranosyl-(1→6)-β-D-glucopyranosyl ester; and
(iii) 13-({β-D-glucopyranosyl-(1→2)-[β-D-glucopyranosyl-(1→3)-]β-D-glucopyranosyl}oxy)ent-kaur-16-en-19-oic acid α-D-glucopyranosyl-(1→3)-α-D-glucopyranosyl-(1→6)-β-D-glucopyranosyl ester.
15. (canceled)
16. A sweetening composition comprising at least one modified steviol glycoside according to claim 13 .
17. A consumable comprising at least one modified steviol glycoside according to claim 13 , optionally combined with other sweetener and/or sweetness enhancer.
18. The consumable according to claim 17 , selected from the group consisting of beverages, foodstuff, an oral care product, a tobacco product, a pharmaceutical products and nutraceutical products.
19.-22. (canceled)
23. A sweetening composition comprising at least one modified steviol glycoside according to claim 14 .
24. A consumable comprising at least one modified steviol glycoside according to claim 14 , optionally combined with other sweetener and/or sweetness enhancer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/899,709 US20200325515A1 (en) | 2015-03-10 | 2020-06-12 | Methods for the Enzymatic Modification of Steviol Glycosides, Modified Steviol Glycosides Obtainable Thereby, and the Use Thereof as Sweeteners |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15158421.6 | 2015-03-10 | ||
EP15158421 | 2015-03-10 | ||
PCT/NL2016/050172 WO2016144175A1 (en) | 2015-03-10 | 2016-03-10 | Methods for the enzymatic modification of steviol glycosides, modified steviol glycosides obtainable thereby, and the use thereof as sweeteners |
US201715556846A | 2017-09-08 | 2017-09-08 | |
US16/899,709 US20200325515A1 (en) | 2015-03-10 | 2020-06-12 | Methods for the Enzymatic Modification of Steviol Glycosides, Modified Steviol Glycosides Obtainable Thereby, and the Use Thereof as Sweeteners |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NL2016/050172 Division WO2016144175A1 (en) | 2015-03-10 | 2016-03-10 | Methods for the enzymatic modification of steviol glycosides, modified steviol glycosides obtainable thereby, and the use thereof as sweeteners |
US15/556,846 Division US10731195B2 (en) | 2015-03-10 | 2016-03-10 | Methods for the enzymatic modification of steviol glycosides, modified steviol glycosides obtainable thereby, and the use thereof as sweeteners |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200325515A1 true US20200325515A1 (en) | 2020-10-15 |
Family
ID=52784894
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/556,846 Active US10731195B2 (en) | 2015-03-10 | 2016-03-10 | Methods for the enzymatic modification of steviol glycosides, modified steviol glycosides obtainable thereby, and the use thereof as sweeteners |
US16/899,709 Abandoned US20200325515A1 (en) | 2015-03-10 | 2020-06-12 | Methods for the Enzymatic Modification of Steviol Glycosides, Modified Steviol Glycosides Obtainable Thereby, and the Use Thereof as Sweeteners |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/556,846 Active US10731195B2 (en) | 2015-03-10 | 2016-03-10 | Methods for the enzymatic modification of steviol glycosides, modified steviol glycosides obtainable thereby, and the use thereof as sweeteners |
Country Status (6)
Country | Link |
---|---|
US (2) | US10731195B2 (en) |
EP (1) | EP3268487A1 (en) |
JP (1) | JP6976173B2 (en) |
CN (1) | CN107532189B (en) |
BR (1) | BR112017019290A2 (en) |
WO (1) | WO2016144175A1 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10517321B2 (en) | 2015-07-10 | 2019-12-31 | Sweet Green Fields USA LLC | Compositions of steviol multiglycosylated derivatives and stevia components |
US11542536B2 (en) | 2016-12-14 | 2023-01-03 | The Coca-Cola Company | Preparing novel steviol glycosides by bioconversion |
CN117752032A (en) * | 2017-04-25 | 2024-03-26 | 可口可乐公司 | Sweetness and taste improvement of dihydrochalcones on steviol glycosides and mogroside sweeteners |
JP6967153B2 (en) * | 2017-12-15 | 2021-11-17 | シージェイ チェイルジェダン コーポレイション | Method for Producing Glucose-Translocated Steviol Glycoside Using Lactobacillus-Mali |
GB201805576D0 (en) * | 2018-04-04 | 2018-05-16 | Optibiotix Ltd | Sweeteners and methods of production thereof |
US11312948B2 (en) | 2018-05-25 | 2022-04-26 | Bontac Bio-Engineering (Shenzhen) Co., Ltd | Method and enzyme for preparation of enzyme-modified stevia sugar and use of enzyme-modified stevia sugar |
CN108727443A (en) * | 2018-06-29 | 2018-11-02 | 东台市浩瑞生物科技有限公司 | Improve crystallisation, its product and the purposes of rebaudioside A 1G contents |
WO2020001516A1 (en) * | 2018-06-29 | 2020-01-02 | 东台市浩瑞生物科技有限公司 | Stevioside derivative rebaudioside a1g, preparation, purification and application thereof |
CN109097423B (en) * | 2018-08-13 | 2021-05-28 | 江南大学 | Catalytic synthesis of mono-and di-glucosyl rebaudioside A by applying alternan sucrase |
JP2021533729A (en) * | 2018-08-22 | 2021-12-09 | フイルメニツヒ ソシエテ アノニムFirmenich Sa | Terpene glycoside derivatives and their use |
CN113301810B (en) * | 2019-01-17 | 2023-08-15 | 北京绿色金可生物技术股份有限公司 | Method for transglucosylation of steviol glycoside and steviol glycoside composition thereof |
KR20200109775A (en) * | 2019-03-14 | 2020-09-23 | 씨제이제일제당 (주) | Composition comprising transglycosylated stevioside and transglycosylated rebaudioside A |
KR102303661B1 (en) * | 2019-06-14 | 2021-09-23 | 씨제이제일제당 주식회사 | Compositions comprising glucose transferase for producing glucosylated steviol glycosides and method for producing glucosylated steviol glycosides using the same |
KR102303415B1 (en) * | 2019-06-14 | 2021-09-23 | 씨제이제일제당 (주) | Sweetening material composition and preparation method thereof |
WO2021252814A1 (en) * | 2020-06-11 | 2021-12-16 | Corn Products Development, Inc. | Production and uses of oligosaccharides and steviol glycosides |
KR102546737B1 (en) * | 2020-11-25 | 2023-06-22 | 씨제이제일제당 주식회사 | Composition comprising transglycosylated steviol glycoside |
GB202112610D0 (en) * | 2021-09-03 | 2021-10-20 | Optibiotix Ltd | Sweetener compositions and methods of production thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US697430A (en) * | 1900-06-12 | 1902-04-15 | Fox Machine Company | Type-writing machine. |
JPS5523756A (en) | 1978-08-07 | 1980-02-20 | Tokyo Shibaura Electric Co | Controller |
US5962678A (en) | 1996-09-13 | 1999-10-05 | Alberta Research Council | Method of extracting selected sweet glycosides from the Stevia rebaudiana plant |
US7923552B2 (en) | 2004-10-18 | 2011-04-12 | SGF Holdings, LLC | High yield method of producing pure rebaudioside A |
US9386797B2 (en) | 2011-02-17 | 2016-07-12 | Purecircle Sdn Bhd | Glucosyl stevia composition |
US8257948B1 (en) * | 2011-02-17 | 2012-09-04 | Purecircle Usa | Method of preparing alpha-glucosyl Stevia composition |
US7862845B2 (en) | 2005-10-11 | 2011-01-04 | Purecircle Sdn Bhd | Process for manufacturing a sweetener and use thereof |
WO2012128775A1 (en) | 2011-03-22 | 2012-09-27 | Purecircle Usa | Glucosylated steviol glycoside composition as a taste and flavor enhancer |
US8791253B2 (en) | 2006-06-19 | 2014-07-29 | The Coca-Cola Company | Rebaudioside A composition and method for purifying rebaudioside A |
US20130071521A1 (en) | 2007-03-14 | 2013-03-21 | Pepsico, Inc. | Rebaudioside d sweeteners and food products sweetened with rebaudioside d |
KR20130014227A (en) * | 2011-07-29 | 2013-02-07 | 한국생명공학연구원 | NOVEL α-GLUCOSYL STEVIOSIDES AND PROCESS FOR PRODUCING THE SAME |
EP2770843B1 (en) * | 2011-10-24 | 2017-08-09 | Givaudan SA | Sweetness enhancing composition comprising stevioside and rebaudioside a |
CN102492757B (en) * | 2011-11-25 | 2014-04-09 | 中国农业大学 | Method for improving taste quality of stevioside by using beta-cyclodextrin glucosyltransferase |
RU2599166C2 (en) | 2011-12-19 | 2016-10-10 | Дзе Кока-Кола Компани | Methods for purifying steviol glycosides and use thereof |
CN102492673B (en) * | 2011-12-28 | 2013-01-23 | 江南大学 | Method for producing alternan sucrase by fermenting Leuconostoccitreum and its application |
AU2013211605B2 (en) * | 2012-01-23 | 2017-04-06 | Dsm Ip Assets B.V. | Diterpene production |
CN103974628B (en) * | 2012-05-22 | 2019-04-05 | 谱赛科有限责任公司 | The steviol glycoside of high-purity |
CN102940183A (en) * | 2012-11-09 | 2013-02-27 | 江南大学 | Biological processing method for regulating and improving taste quality of stevioside |
CA3171770A1 (en) | 2013-02-06 | 2014-08-14 | Evolva Sa | Methods for improved production of rebaudioside d and rebaudioside m |
-
2016
- 2016-03-10 JP JP2017547452A patent/JP6976173B2/en active Active
- 2016-03-10 BR BR112017019290A patent/BR112017019290A2/en active Search and Examination
- 2016-03-10 WO PCT/NL2016/050172 patent/WO2016144175A1/en active Application Filing
- 2016-03-10 US US15/556,846 patent/US10731195B2/en active Active
- 2016-03-10 CN CN201680022567.6A patent/CN107532189B/en active Active
- 2016-03-10 EP EP16718510.7A patent/EP3268487A1/en active Pending
-
2020
- 2020-06-12 US US16/899,709 patent/US20200325515A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP6976173B2 (en) | 2021-12-08 |
JP2018509902A (en) | 2018-04-12 |
EP3268487A1 (en) | 2018-01-17 |
WO2016144175A1 (en) | 2016-09-15 |
US20180044708A1 (en) | 2018-02-15 |
US10731195B2 (en) | 2020-08-04 |
BR112017019290A2 (en) | 2018-05-02 |
CN107532189B (en) | 2021-12-17 |
CN107532189A (en) | 2018-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200325515A1 (en) | Methods for the Enzymatic Modification of Steviol Glycosides, Modified Steviol Glycosides Obtainable Thereby, and the Use Thereof as Sweeteners | |
EP2188300B1 (en) | Novel sweetener iso-mogroside v | |
US11788070B2 (en) | Uridine diphosphate-dependent glycosyltransferase enzyme | |
US20210107933A1 (en) | High-purity steviol glycosides | |
WO2012128775A1 (en) | Glucosylated steviol glycoside composition as a taste and flavor enhancer | |
US20210246156A1 (en) | High-purity steviol glycosides | |
CN112513059A (en) | High purity steviol glycosides | |
WO2018106983A1 (en) | Glucosyl stevia compositons | |
CN112512337A (en) | High purity steviol glycosides | |
US20210147892A1 (en) | Terpene glycoside derivatives and uses thereof | |
WO2023083163A1 (en) | Sweetener and flavor composition comprising glycosylated high purity steviol glycosides | |
CN113301810B (en) | Method for transglucosylation of steviol glycoside and steviol glycoside composition thereof | |
US20220175002A1 (en) | Compositions comprising mogrosides, steviol glycosides and glycosylated derivatives thereof and methods of enhancing the mouthfeel or sweetness of consumables | |
US20230085655A1 (en) | Glucosyl stevia compositions | |
JP2023182635A (en) | Composition including glucosylated terpene glycoside, terpene glycoside and cyclodextrine | |
US20210368839A1 (en) | Glucosyl stevia compositions | |
CN117730086A (en) | High purity steviol glycosides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: RIJKSUNIVERSITEIT GRONINGEN, NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TE POELE, EVELIEN MARIA;DIJKHUIZEN, LUBBERT;GERWIG, GERRIT JOHANNES;AND OTHERS;SIGNING DATES FROM 20171006 TO 20171013;REEL/FRAME:052922/0282 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |